var title_f3_23_3440="Bridging septal perforators";
var content_f3_23_3440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Myocardial bridging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right anterior oblique view shows myocardial bridging during systole of the major septal perforator (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3440=[""].join("\n");
var outline_f3_23_3440=null;
var title_f3_23_3441="United States map of TB case rates 2011";
var content_f3_23_3441=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Rate* of tuberculosis cases, United States 2011",
"    <sup>",
"     &bull;",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 394px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Per 100,000 population.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Data are provisional.",
"    </div>",
"    <div class=\"reference\">",
"     CDC. Trends in tuberculosis - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:181.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3441=[""].join("\n");
var outline_f3_23_3441=null;
var title_f3_23_3442="OIT food allergy";
var content_f3_23_3442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51554&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral immunotherapy for IgE-mediated food allergy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Foods",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subjects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to maintenance/ maintenance dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Success rate*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schofield AT. Lancet 1908; 1:716.",
"       </td>",
"       <td>",
"        Egg",
"       </td>",
"       <td>",
"        n = 1",
"       </td>",
"       <td>",
"        1/10,000 of an egg",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"       <td>",
"        <p>",
"         Negative oral food challenge to egg after&nbsp;six months.",
"        </p>",
"        <p>",
"         The subject continued to ingest an egg daily.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Patriarca G, et al. Allergol Immunopathol (Madr) 1984; 12:275. Open clinical trial.",
"       </td>",
"       <td>",
"        CM (8)",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         n = 19",
"        </p>",
"        <p>",
"         Age: 5 to 55 years",
"        </p>",
"       </td>",
"       <td>",
"        10 drops of CM in 10 mL of water; 4 drops/day",
"       </td>",
"       <td>",
"        100 mL of undiluted CM/day in 104 days",
"       </td>",
"       <td>",
"        5/8",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         Side effects in 11 of 19 patients: urticaria, pruritus, emesis, angioedema, abdominal pain, rhinitis, dyspnea.",
"        </p>",
"        <p>",
"         Patients followed for 3 to 12 months.",
"        </p>",
"        <p>",
"         Subject with orange allergy reported resolution of allergy to plums and peaches.",
"        </p>",
"        <p>",
"         No insight into mechanism of desensitization.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg (8)",
"       </td>",
"       <td>",
"        10 drops of beaten egg in 100 mL of water, 4 drops/day",
"       </td>",
"       <td>",
"        120 drops of pure beaten egg/day in 90 days",
"       </td>",
"       <td>",
"        6/8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fish (2)",
"       </td>",
"       <td>",
"        10 mL of mixed fish commercial extract (eel, sardine, codfish, anchovy) in 90 mL of water, 4 drops/day",
"       </td>",
"       <td>",
"        200 g of cooked fish/day in 120 days",
"       </td>",
"       <td>",
"        2/2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orange (1)",
"       </td>",
"       <td>",
"        Unspecified",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shenassa MM. J Allergy Clin Immunol 1985; 75:177S.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        n = 6",
"       </td>",
"       <td>",
"        0.05 mL of the strongest dilution of peanut extract 1:10 weight/volume that caused no erythema on PST",
"       </td>",
"       <td>",
"        Not specified",
"       </td>",
"       <td>",
"        4/6",
"       </td>",
"       <td>",
"        <p>",
"         Four subjects reported to tolerate peanut daily.",
"        </p>",
"        <p>",
"         Two subjects did not complete the desensitization protocol.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patriarca G. Hepatogastroenterology 1998; 45:52. Clinical trial.",
"       </td>",
"       <td>",
"        <p>",
"         CM (6)",
"        </p>",
"        <p>",
"         Egg (5)",
"        </p>",
"        <p>",
"         Fish (2)",
"        </p>",
"        <p>",
"         Apple (1)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         n = 14",
"        </p>",
"        <p>",
"         Age: 4 to 14 years",
"        </p>",
"       </td>",
"       <td>",
"        Modification of previously published protocol",
"       </td>",
"       <td>",
"        Modification of previously published protocol",
"       </td>",
"       <td>",
"        12/14",
"       </td>",
"       <td>",
"        <p>",
"         All of the children who achieved maintenance continued to tolerate the foods at least&nbsp;two to&nbsp;three times per week for&nbsp;three to&nbsp;six years.",
"        </p>",
"        <p>",
"         10 of 14 patients experienced side effect during treatment.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bauer A, et al. Allergy 1999; 54:894.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 1",
"        </p>",
"        <p>",
"         Age: 12 years",
"        </p>",
"       </td>",
"       <td>",
"        1 mL/day of 0.01 percent milk diluted in water",
"       </td>",
"       <td>",
"        Rush protocol: dose doubled every other hour; final dose 200 mL of undiluted milk achieved in&nbsp;five days",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"       <td>",
"        Patient tolerated CM daily for at least&nbsp;six months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nucera E, et al. Dig Dis Sci 2000; 45:637.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 1",
"        </p>",
"        <p>",
"         Age:&nbsp;6 years",
"        </p>",
"       </td>",
"       <td>",
"        10 drops of milk in 10 mL of water; 4 drops per day",
"       </td>",
"       <td>",
"        100 mL of undiluted CM/day in 104 days",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"       <td>",
"        <p>",
"         Child able to ingest CM and dairy products after&nbsp;six months.",
"        </p>",
"        <p>",
"         After&nbsp;seven months: SPT to BLG, ALA, CS became negative; IgE to milk proteins decreased significantly, whereas milk-IgG and IgA increased.",
"        </p>",
"        <p>",
"         PBMC stimulated with BLG produced significantly less IL-4 at 18 months than at baseline.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rueff F, et al. Allergy 2001; 56:82.",
"       </td>",
"       <td>",
"        Celery",
"       </td>",
"       <td>",
"        <p>",
"         n = 1",
"        </p>",
"        <p>",
"         Age: 49 years",
"        </p>",
"       </td>",
"       <td>",
"        0.1 mL of a commercial natural celery juice&nbsp;five times a day",
"       </td>",
"       <td>",
"        5 mL&nbsp;five times daily for&nbsp;three months",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"       <td>",
"        <p>",
"         At&nbsp;three months, patient tolerated 10 g of raw celery, but developed flushing to 20 g.",
"        </p>",
"        <p>",
"         Patient continued to ingest 25 mL of raw celery juice for&nbsp;three years.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patriarca G, et al. Aliment Pharmacol Ther 2003; 17:459. Clinical trial.",
"       </td>",
"       <td>",
"        <p>",
"         CM (29)",
"        </p>",
"        <p>",
"         Egg (15)",
"        </p>",
"        <p>",
"         Fish (11)",
"        </p>",
"        <p>",
"         Orange (2); and other&bull;",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         n = 59",
"        </p>",
"        <p>",
"         Age: 3 to 55 years",
"        </p>",
"       </td>",
"       <td>",
"        Modification of previously published protocol",
"       </td>",
"       <td>",
"        Modification of previously published protocol",
"       </td>",
"       <td>",
"        45/54 (83.3 percent)",
"       </td>",
"       <td>",
"        <p>",
"         51 percent of patients experienced urticaria, emesis, diarrhea, or abdominal pain.",
"        </p>",
"        <p>",
"         In 9 patients (16.7 percent), protocol was stopped due to side effects.",
"        </p>",
"        <p>",
"         No differences between children and adults.",
"        </p>",
"        <p>",
"         SPT became negative after 18 months in 78 percent; Food-IgE decreased and food-IgG4 increased after 18 months.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meglio P, et al. Allergy 2004; 59:980.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 21",
"        </p>",
"        <p>",
"         Age: 5 to 10 years",
"        </p>",
"       </td>",
"       <td>",
"        1 drop of CM diluted 1:25 in water",
"       </td>",
"       <td>",
"        200 mL undiluted CM per day over 180 days",
"       </td>",
"       <td>",
"        15/21 (71.4 percent)",
"       </td>",
"       <td>",
"        <p>",
"         3 of 21 reacted to minimal dose of diluted CM; 3 of 21 tolerated only 40 to 80 CM/day; 15 of 21 tolerated 200 ml CM/day for&nbsp;six months.",
"        </p>",
"        <p>",
"         Side effect rate 13 of 21.",
"        </p>",
"        <p>",
"         SPT to BLG and CS significantly decreased at&nbsp;six months (p&lt;0.001); CM-IgE levels not significantly different.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Rolinck-Werninghaus C, et al. Allergy 2005; 60:1320.",
"       </td>",
"       <td>",
"        CM (1)",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         n = 3",
"        </p>",
"        <p>",
"         Age: 4 to 12 years",
"        </p>",
"       </td>",
"       <td>",
"        0.0006 mL of CM per day",
"       </td>",
"       <td>",
"        100 mL CM per day over 37 weeks",
"       </td>",
"       <td rowspan=\"2\">",
"        3/3",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         All patients had acute symptoms to food re-exposure following discontinuation of food for 2 to 14 days.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg (2)",
"       </td>",
"       <td>",
"        0.01 mg egg per day at home",
"       </td>",
"       <td>",
"        2.5 g egg per day (1/2 egg) over 41 to 52 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patriarca G, et al. Dig Dis Sci 2006; 51:471.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        <p>",
"         n = 1",
"        </p>",
"        <p>",
"         Age: 38 years",
"        </p>",
"       </td>",
"       <td>",
"        5.6 mg peanut per day on day 1",
"       </td>",
"       <td>",
"        40 g peanut/day over 7 days in the hospital",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"       <td>",
"        SPT to peanut became negative at&nbsp;six months; no significant changes in peanut-IgE (baseline 2.1,&nbsp;six months-1.5) or peanut-IgG.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buchanan AD, et al. J Allerg Clin Immunol 2006; 117:S327.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        <p>",
"         n = 7",
"        </p>",
"        <p>",
"         Mean age: 4.4 years",
"        </p>",
"       </td>",
"       <td>",
"        Not specified",
"       </td>",
"       <td>",
"        Rush phase and dose escalation in the hospital, maintenance at home",
"       </td>",
"       <td>",
"        7/7 at&nbsp;six months",
"       </td>",
"       <td>",
"        <p>",
"         During rush phase,&nbsp;four of&nbsp;seven required oral antihistamine.",
"        </p>",
"        <p>",
"         At&nbsp;six months, there was mean 2.3-fold increase in peanut-IgG, and mean change of peanut-IgE of 0.9-fold.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mansfield L. Ann Allergy Asthma Immunol 2006; 97:266.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        <p>",
"         n = 1",
"        </p>",
"        <p>",
"         Age:&nbsp;6 years (with history of anaphylaxis to peanut)",
"        </p>",
"       </td>",
"       <td>",
"        Half a peanut kernel 3 times daily",
"       </td>",
"       <td>",
"        Initial dose and dose increases in the allergy office over&nbsp;eight weeks, maintenance&nbsp;two whole peanuts twice daily",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"       <td>",
"        <p>",
"         Accidental exposures (contact and ingestion) tolerated without symptoms.",
"        </p>",
"        <p>",
"         Peanut-IgE [kIU/L] was &gt;100 at baseline, 74 at 6 months, and 42 at 12 months.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Buchanan J, et al. Allergy Clin Immunol 2007; 119:199.",
"       </td>",
"       <td>",
"        Egg",
"       </td>",
"       <td>",
"        <p>",
"         n = 7",
"        </p>",
"        <p>",
"         Mean age:&nbsp;4 years (subjects with history of egg-induced anaphylaxis were excluded)",
"        </p>",
"       </td>",
"       <td>",
"        0.1 mg of powdered egg white followed by doubling doses every 30 minutes until the highest tolerated dose was determined",
"       </td>",
"       <td>",
"        Modified rush and build up phase in the hospital, maintenance dosing once a day at home. Increases by 25 mg every&nbsp;two weeks until 150 mg, then by 50 mg until reaching maintenance of 300 mg.",
"       </td>",
"       <td>",
"        4/7",
"       </td>",
"       <td>",
"        <p>",
"         Four subjects tolerated egg challenge at the end of 24 months. Two of them reacted to a subsequent egg challenge done&nbsp;three months after treatment was stopped.",
"        </p>",
"        <p>",
"         Egg-specific IgG increased significantly from baseline to 24 months (p = 0.002).",
"        </p>",
"        <p>",
"         Five subjects showed an overall decrease in egg-specific IgE.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Morisset M, et al. Eur Ann Allergy Clin Immunol 2007; 39:12.",
"       </td>",
"       <td>",
"        CM (57)",
"       </td>",
"       <td>",
"        <p>",
"         n = 141",
"        </p>",
"        <p>",
"         Mean age: 2.2 years",
"        </p>",
"       </td>",
"       <td>",
"        1 mL/day",
"       </td>",
"       <td>",
"        Home build-up over&nbsp;six weeks, up to a dose of 250 mL/day",
"       </td>",
"       <td>",
"        89 percent",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Only children tolerating at least 60 mL of CM or 965 mg of raw egg white on a baseline food challenge were included.",
"        </p>",
"        <p>",
"         SPT sizes and specific IgE levels were significantly decreased in children that developed tolerance to CM or egg.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg (84)",
"       </td>",
"       <td>",
"        <p>",
"         n = 141",
"        </p>",
"        <p>",
"         Mean age: 3.5 years",
"        </p>",
"       </td>",
"       <td>",
"        1 g of hardboiled egg yolk",
"       </td>",
"       <td>",
"        Home build-up over&nbsp;four weeks to 4 g of yolk and 4 g of egg white once a day, every other day",
"       </td>",
"       <td>",
"        69 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Staden U, et al. Allergy 2007; 62:1261.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        CM-14",
"       </td>",
"       <td>",
"        CM-0.02 mg protein",
"       </td>",
"       <td rowspan=\"2\">",
"        Slow induction phase at home, median duration&nbsp;seven months, followed by a maintenance phase of CM 3300 mg (100 mL) and HE 2800 mg (1/2 egg); median duration&nbsp;nine months",
"       </td>",
"       <td rowspan=\"2\">",
"        9 of 25 (36 percent) permanent tolerance, 3 of 25 (12 percent) tolerant with regular intake (desensitized), 4 of 25 (16 percent) partial responders",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         The first randomized trial to test the permanence of the therapeutic effect following a two-month period of complete avoidance of the food.",
"        </p>",
"        <p>",
"         The spontaneous resolution rate of food allergy in the control group was comparable, 7 of 20 (35 percent), to that seen in the treatment group.",
"        </p>",
"        <p>",
"         Allergen-specific IgE decreased significantly both in children who developed natural tolerance during the elimination diet (p&lt;0.05) and in those treated with OIT (p&lt;0.001).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HE",
"       </td>",
"       <td>",
"        HE-11; control group = 20",
"       </td>",
"       <td>",
"        HE-0.006 mg protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Longo G, et al. J Allergy Clin Immunol 2008; 121:343.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 60",
"        </p>",
"        <p>",
"         Mean age: 7.9 years (5 to 17)",
"        </p>",
"       </td>",
"       <td>",
"        5 drops of 1 drop of CM in 10 mL of water",
"       </td>",
"       <td>",
"        10 day rush phase in the hospital, followed by home dosing, goal of minimum 150 mL CM/day for&nbsp;one year",
"       </td>",
"       <td>",
"        After one year, 11 of 30 tolerated &gt;150 mL CM and 16 of 30 tolerated 5 to 150 mL CM",
"       </td>",
"       <td>",
"        Three children discontinued the study due to significant respiratory or abdominal side effects. 17 of 30 children reported side effects at home: 17 children received orals steroids, six received nebulized epinephrine, and one received intramuscular epinephrine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skripak JM, et al. J Allergy Clin Immunol 2008; 122:1154.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        n = 20; active to placebo 2:1 ratio",
"       </td>",
"       <td>",
"        0.4 mg CM protein",
"       </td>",
"       <td>",
"        Dose increase every&nbsp;one to&nbsp;two weeks, 12 mg minimum tolerated dose to proceed to home dosing; maximum dose 500 mg",
"       </td>",
"       <td>",
"        13 weeks to repeat DBPCFC",
"       </td>",
"       <td>",
"        <p>",
"         After OIT, the median cumulative dose of milk inducing a reaction in the active group increased from 40 mg to 5140 mg; there was no change in the placebo group.",
"        </p>",
"        <p>",
"         The median frequency of side effects was 35 percent in the active group compared with one percent in the placebo group.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narisety SD, et al. J Allergy Clin Immunol 2009; 124:610.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 15",
"        </p>",
"        <p>",
"         Age: 6 to 16 years",
"        </p>",
"       </td>",
"       <td>",
"        500 mg CM (median)",
"       </td>",
"       <td>",
"        Dose increase by &le;50 percent every two weeks",
"       </td>",
"       <td>",
"        Median f/u 17 weeks, range 13 to 75",
"       </td>",
"       <td>",
"        Six patients tolerated 16,000 mg with no reaction, and seven reacted at 3000 to 16,000 mg. Adverse reactions were common and largely unpredictable, with several systemic reactions occurring at previously tolerated doses, often in the setting of exercise or viral illness. However, the overall rate of reactions decreased over time, even as milk doses increased. In one subject, apparent clinical reactivity to milk recurred, primarily manifesting with gastrointestinal symptoms, suggesting possible eosinophilic disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jones SM, et al. J Allergy Clin Immunol 2009; 124:292.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        n = 29",
"       </td>",
"       <td>",
"        0.1 mg peanut protein",
"       </td>",
"       <td>",
"        Initial day escalation phase 0.1 mg peanut protein doubled every 30 minutes, up to 50 mg. Build-up phase: increase by 25 mg every&nbsp;two weeks, up to 300 mg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Open label study. Twenty-seven patients tolerated ingestion of 3.9 g peanut protein during the final food challenge. Most symptoms noted during OIT resolved spontaneously or with antihistamines. By six months, titrated skin prick tests and activation or basophils decreased significantly. Follow-up for 30 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hofmann AM, et al. J Allergy Clin Immunol 2009; 124:286.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        n = 20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        During the initial escalation, the risk of mild wheezing was 18 percent. The probability of having any symptoms after a build-up phase dose was 46 percent, with a risk of 29 percent for skin symptoms. The risk of reaction with any home dose was 3.5 percent; upper respiratory tract (1.2 percent) and skin (1.1 percent) symptoms being most common. Treatment was given for 0.7 percent of home doses. Two subjects received epinephrine after one home dose each.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clark AT, et al. Allergy 2009; 64:1218.",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        n = 4",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        Dose increase every&nbsp;two weeks up to 800 mg",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Each subject tolerated at least 10 whole peanuts (approximately 2.38 g protein) in post-IT challenges, an increase in dose threshold of 48- to 478-fold for the four subjects. Adverse reactions were mild.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blumchen K, et al. J Allergy Clin Immunol 2010; 126:83",
"       </td>",
"       <td>",
"        Peanut&nbsp;",
"       </td>",
"       <td>",
"        n = 23",
"       </td>",
"       <td>",
"        OIT was started with approximately 1/100 of the eliciting reaction dose during the baseline DBPCFC, range 0.8 mg to 24 mg",
"       </td>",
"       <td>",
"        14 patients required a median of seven months (range 0 to 560 days) to reach their individual stable maintenance dose (0.5 to 2 g peanut) after the rush phase",
"       </td>",
"       <td>",
"        <p style=\"margin: 0in 0in 10pt;\">",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          After the rush phase, patients tolerated a median 0.15 g peanut. 22 of 23 patients continued with the long-term protocol. After a median&nbsp;seven months, 14 (63 percent) patients reached the protective dose 0.5 to 2 g peanut. At the final DBPCFC, patients tolerated a median 1 g (range, 0.3 to 4 g) in comparison with 0.2 g peanut at the DBPCFC pre-OIT (range, 0.02 to 1 g),&nbsp;p",
"          <em>",
"          </em>",
"          = 0.002.",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         In 2.6 percent of 6137 total daily doses, mild to moderate side effects were observed; in 1.3 percent, lower respiratory symptoms occurred. OIT was discontinued in 4 of 22 (18 percent) patients because of adverse events. No epinephrine was used for treatment of adverse reactions.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varshney P, et al. J Allergy Clin Immunol 2011; 127:654.",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Peanut",
"       </td>",
"       <td>",
"        &nbsp;n = 28",
"       </td>",
"       <td>",
"        0.1 mg",
"       </td>",
"       <td>",
"        Initial escalation day: 0.1 mg to 6 mg, subjects not tolerating 1.5 mg were withdrawn from the study; dose escalation lasted 44 weeks, maintenance phase lasted one month; the oral food challenge was done at 48 weeks",
"       </td>",
"       <td>",
"        <p style=\"margin: 0in 0in 10pt;\">",
"         <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"          Peanut OIT subjects reached OFC after a median of 12.4 months on treatment (range, 11.3 to 16.3 months) versus 11.7 months for placebo-treated subjects (range, 11 to 13.8 months;&nbsp;p&nbsp;= 0.07). All peanut OIT subjects reaching OFC (n&nbsp;= 16) ingested the maximum cumulative dose of 5000 mg (approximately 20 peanuts), whereas placebo subjects (n&nbsp;=&nbsp;9) ingested a median cumulative dose of 280 mg (range, 0 to 1900 mg; p&lt;0.001).",
"         </span>",
"        </p>",
"       </td>",
"       <td>",
"        <span style=\"line-height: 115%; font-family: verdana,sans-serif; font-size: 9pt;\">",
"         During the initial escalation day, 9 (47 percent) of 19 peanut OIT subjects experienced clinically relevant side effects requiring antihistamine treatment. Of these,&nbsp;two were treated with epinephrine. Peanut OIT subjects had clinically relevant symptoms after 1.2 percent&nbsp;of 407 build-up doses on the research unit. None required treatment with epinephrine or hospitalization. One peanut OIT subject withdrew from the study after the first dose escalation because of mild gastrointestinal symptoms. No peanut OIT subjects needed epinephrine with home doses;&nbsp;one placebo subject was given epinephrine at home for symptoms with a placebo dose.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keet CA, et al. J Allergy Clin Immunol 2012; 129:448.",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 30",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Age: 6 to 17 years",
"        </p>",
"       </td>",
"       <td>",
"        0.0000017 mg",
"       </td>",
"       <td>",
"        Children with CM allergy were randomized to SLIT alone or SLIT followed by OIT. SLIT initial escalation day: 0.0000017 mg to 0.07 mg. SLIT build-up phase: dose increased every&nbsp;one to&nbsp;two weeks up to 3.73 mg. SLIT/SLIT advanced to 7 g in two dose increases. SLIT/OIT advanced to 985 (OITB) or 1969 (OITA) in 14 dose increases. Challenges with 8 g of milk protein were performed after 12 and 60 weeks of maintenance. Therapy was withdrawn if the 60-week challenge was passed, with challenges repeated&nbsp;one and&nbsp;six weeks later.",
"       </td>",
"       <td>",
"        After therapy, 1 of 10 subjects in the SLIT group, 6 of 10 subjects in the SLIT/OITB group, and 8 of 10 subjects in the OITA group passed the 8 g challenge (p = 0.002, SLIT versus OIT). After avoidance, 6 of 15 subjects (3 of 6 subjects in the OITB group and 3 of 8 subjects in the OITA group) regained reactivity, two after one week.",
"       </td>",
"       <td>",
"        <p>",
"         The overall reaction rate was similar, but systemic reactions were more common during OIT than during SLIT. By the end of therapy, titrated CM skin prick test results and CD63 and CD203c expression decreased and CM-specific IgG4 levels increased in all groups, whereas CM-specific IgE and spontaneous histamine release values decreased in only the OIT group.",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Six of 15 subjects who passed a full milk challenge after 60 weeks of maintenance lost desensitization within&nbsp;six weeks. However, after avoidance, the lowest reaction threshold was equivalent to about 2.5 oz of milk, which was well above most accidental exposures, and most did not react until a full cup of milk.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burks AW, et al. NEJM 2012; 367:233.",
"       </td>",
"       <td>",
"        Egg",
"       </td>",
"       <td>",
"        <p>",
"         n = 55",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Age: 5 to 11 years",
"        </p>",
"       </td>",
"       <td>",
"        0.1 mg raw egg white powder",
"       </td>",
"       <td>",
"        In this randomized, double-blind, placebo-controlled trial, 40 children received OIT and 15 received placebo. Oral food challenges with egg white powder were done at 10 months and at 22 months. Children who successfully passed the challenge at 22 months discontinued OIT and avoided all egg consumption for four to six weeks. At 24 months, these children underwent an oral food challenge with egg white powder and a cooked egg to test for sustained unresponsiveness. Children who passed this challenge at 24 months were placed on a diet with unlimited egg consumption and were evaluated for continuation of sustained unresponsiveness at 30 months and 36 months.",
"       </td>",
"       <td>",
"        After 10 months of therapy, none of the placebo-controlled children and 55 percent of OIT-treated children passed the oral food challenge and were considered to be desensitized; after 22 months, 75 percent of children in the oral immunotherapy group were desensitized. In the oral immunotherapy group, 28 percent (11 of 40 children) passed the oral food challenge at 24 months and were considered to have sustained unresponsiveness. At 30 months and 36 months, all children who had passed the oral food challenge at 24 months were consuming egg.",
"       </td>",
"       <td>",
"        Small wheal diameters on skin prick testing and increases in egg-specific IgG4 antibody levels were associated with passing the oral food challenge at 24 months (ie, sustained unresponsiveness).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmivesi S, et al. Acta Paediatr 2013; 102:172.",
"       </td>",
"       <td>",
"        CM",
"       </td>",
"       <td>",
"        <p>",
"         n = 28 enrolled, 24 completed",
"        </p>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Age: 6 to 14 years",
"        </p>",
"       </td>",
"       <td>",
"        0.06 mg CM protein",
"       </td>",
"       <td>",
"        Randomized, double-blind, placebo-controlled OIT study; 16 children in the active and 8 in the placebo groups. CM allergy was documented with an open milk challenge within&nbsp;six months prior to enrollment. OIT was done with pasteurized 2.5 percent&nbsp;fresh cow's milk and with oat/rice or soy milk as placebo. In the OIT group, the amount of milk protein doubled every week, from 0.06 to 6400 mg. The final dose of 6400 mg was given at home on day 162, with a&nbsp;follow-up visit occurring in&nbsp;two weeks.&nbsp;Ten children in the placebo group successfully completed open-label OIT by an identical protocol, and all used daily CM or milk products&nbsp;six months later.",
"        <br/>",
"       </td>",
"       <td>",
"        After 3 to 3.5 years, 22 of 28 children ingested milk daily.",
"       </td>",
"       <td>",
"        Milk OIT in school age children&nbsp;induced long term desensitization. There was no interruption of therapy to test permanent tolerance. Subjective abdominal discomfort and oral pruritus were the most common adverse reactions. Wheezing was reported in 19.2 percent&nbsp;of cases. There were no reports of anaphylaxis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CM: cow's milk; HE: hen's egg; SPT: skin prick test; BLG: beta-lactoglobulin; ALA: alpha-lactalbumin; CS: casein; PBMC: peripheral blood mononuclear cells; SLIT: sublingual immunotherapy.",
"     <br>",
"      * Success rate defined as regular ingestion of the tested food for at least 6 months; The study by Narisety was an open label maintenance therapy, extension of Skripak study; The study by Hofmann reported the long term follow-up of children described by Jones.",
"      <br>",
"       &bull; One of each apple, peach, lettuce, orange, beans, and corn.",
"       <br>",
"        &Delta; The first randomized, controlled study of peanut oral immunotherapy.",
"        <br/>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3442=[""].join("\n");
var outline_f3_23_3442=null;
var title_f3_23_3443="Patient information: Bursitis (The Basics)";
var content_f3_23_3443=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15727\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10640\">",
"         Bursae near the hip",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/2/26671\">",
"          Knee bursa (prepatellar bursa)",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/3/11314\">",
"         Patient information: Gout (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/25/43409\">",
"         Patient information: Hip pain in older people (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?30/10/30881\">",
"         Patient information: Arthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/18/44321\">",
"         Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/46/24289\">",
"         Patient information: Hip pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/4/24642\">",
"         Patient information: Knee pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bursitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bursitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1472858854\">",
"      <span class=\"h1\">",
"       What is bursitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bursitis is a condition that can cause pain or swelling next to a joint. Most of the time, bursitis happens around the shoulder, elbow, hip, or knee. It can also happen around other joints in the body.",
"     </p>",
"     <p>",
"      A &ldquo;bursa&rdquo; is a small fluid-filled sac that sits near a bone. It cushions and protects nearby tissues when they rub on or slide over bones. These sacs, called &ldquo;bursae,&rdquo; are found in many places throughout the body (",
"      <a class=\"graphic graphic_figure graphicRef65477 \" href=\"UTD.htm?10/25/10640\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59257 \" href=\"UTD.htm?26/2/26671\">",
"       figure 2",
"      </a>",
"      ). Bursitis happens when a bursa gets irritated and swollen. This can happen when a person:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Moves a joint over and over again in the same way, over a short period of time",
"       </li>",
"       <li>",
"        Sits on a hard surface or stays in a position that presses on the bursa for a long time",
"       </li>",
"       <li>",
"        Has certain kinds of arthritis, such as gout or rheumatoid arthritis, that can affect their joints and bursae",
"       </li>",
"       <li>",
"        Gets hurt near a bursa",
"       </li>",
"       <li>",
"        Has an infection that spreads to a bursa",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472858861\">",
"      <span class=\"h1\">",
"       What are the symptoms of bursitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of bursitis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain, including when the area is touched",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Trouble moving the joint",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A bursa can get infected if a person gets a cut on the skin nearby. An infected bursa can cause a fever and the area around the bursa to be:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Red",
"       </li>",
"       <li>",
"        Swollen",
"       </li>",
"       <li>",
"        Warm",
"       </li>",
"       <li>",
"        Painful",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have any of the symptoms of an infected bursa, let your doctor or nurse know as soon as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472858868\">",
"      <span class=\"h1\">",
"       Is there a test for bursitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam.",
"     </p>",
"     <p>",
"      If you have symptoms of an infected bursa, your doctor might use a needle to remove some fluid from the bursa. Then he or she can do lab tests on the fluid to find out what is causing the bursitis, and if you need antibiotics.",
"     </p>",
"     <p>",
"      He or she might also order imaging tests, such as an MRI scan or ultrasound. Imaging tests can create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472858875\">",
"      <span class=\"h1\">",
"       What can I do to treat my bursitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To treat your bursitis, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest, cushion, and protect the area &ndash; Try not to irritate the area that hurts. For example, people with very painful shoulder bursitis might need to avoid lifting or carrying heavy things for a while. They might also need to wear an arm sling. People with bursitis behind the heel might need to use a thick heel pad. This can raise the heel so that it does not rub against the back of the shoe.",
"       </li>",
"       <li>",
"        Avoid positions that put pressure on the area &ndash; For example, people with bursitis in the front of the knee should avoid kneeling.",
"       </li>",
"       <li>",
"        Put ice on the area to reduce pain &ndash; Use a frozen bag of peas or a cold gel pack a few times a day for 20 minutes each time.",
"       </li>",
"       <li>",
"        Put heat on the area to reduce pain and stiffness &ndash; Do not use heat for more than 20 minutes at a time. Also, do not use anything too hot that could burn your skin.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472858882\">",
"      <span class=\"h1\">",
"       What other treatments might I have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse might use other treatments, depending on your symptoms and where your bursitis is. Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain-relieving medicines called &ldquo;nonsteroidal anti-inflammatory drugs&rdquo; or &ldquo;NSAIDs&rdquo; &ndash; NSAIDs include",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (also sold as Advil&reg; or Motrin&reg;), and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (also sold as Aleve&reg; or Naprosyn&reg;). These medicines can reduce pain and prevent the bursae from getting swollen and painful.",
"       </li>",
"       <li>",
"        Steroid injections &ndash; During this procedure, a doctor injects a steroid medicine into the area of the bursitis. The medicine used in this treatment is different from the steroids that athletes might take to build muscle.",
"       </li>",
"       <li>",
"        Exercises and stretches &ndash; Your doctor or nurse might recommend that you work with a physical therapist. A physical therapist can teach you stretches and exercises to help reduce your symptoms.",
"       </li>",
"       <li>",
"        Surgery &ndash; A doctor can do surgery if other treatments do not work and you have had symptoms for a long time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People with an infected bursa might also have treatment that includes:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics",
"       </li>",
"       <li>",
"        Having the fluid in the bursa drained &ndash; A doctor can drain the fluid using a needle and syringe, or by doing surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472858889\">",
"      <span class=\"h1\">",
"       Can bursitis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To help reduce the chance that you get bursitis, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Use cushions or pads to avoid putting too much pressure on joints &ndash; For example, people who garden can kneel on a kneeling pad. People who sit for a long time can sit on a cushioned chair.",
"       </li>",
"       <li>",
"        Take breaks, if you are using a certain joint too much",
"       </li>",
"       <li>",
"        Stop an activity or change the way you are doing it, if you feel pain",
"       </li>",
"       <li>",
"        Exercise",
"       </li>",
"       <li>",
"        Lose weight, if you are overweight",
"       </li>",
"       <li>",
"        Use good posture",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1472858896\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=see_link\">",
"       Patient information: Hip pain in older people (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=see_link\">",
"       Patient information: Gout (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=see_link\">",
"       Patient information: Hip pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=see_link\">",
"       Patient information: Knee pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=see_link\">",
"       Patient information: Arthritis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=see_link\">",
"       Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/23/3443?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15727 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3443=[""].join("\n");
var outline_f3_23_3443=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858854\">",
"      What is bursitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858861\">",
"      What are the symptoms of bursitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858868\">",
"      Is there a test for bursitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858875\">",
"      What can I do to treat my bursitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858882\">",
"      What other treatments might I have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858889\">",
"      Can bursitis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1472858896\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10640\">",
"      Bursae near the hip",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/2/26671\">",
"       Knee bursa (prepatellar bursa)",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/10/30881?source=related_link\">",
"      Patient information: Arthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=related_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/3/11314?source=related_link\">",
"      Patient information: Gout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/46/24289?source=related_link\">",
"      Patient information: Hip pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/25/43409?source=related_link\">",
"      Patient information: Hip pain in older people (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/4/24642?source=related_link\">",
"      Patient information: Knee pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3444="Adenosine: Patient drug information";
var content_f3_23_3444=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Adenosine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=see_link\">",
"     see \"Adenosine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=see_link\">",
"     see \"Adenosine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adenocard&reg; IV;",
"     </li>",
"     <li>",
"      Adenoscan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adenocard&reg;;",
"     </li>",
"     <li>",
"      Adenosine Injection, USP;",
"     </li>",
"     <li>",
"      PMS-Adenosine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during a stress test of the heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701443",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to adenosine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Adenoscan&reg;: If you have asthma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Adenoscan&reg;: If you are taking aminophylline, dipyridamole, theophylline, or any drug that has caffeine, talk with your doctor. These drugs may affect how well Adenoscan&reg; works.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Adenoscan&reg;: Do not eat or drink anything that has caffeine (for example, tea, coffee, cola, and chocolate) for 12 hours before using Adenoscan&reg;.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throat, neck, or jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11282 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3444=[""].join("\n");
var outline_f3_23_3444=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130686\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130687\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029407\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029406\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029410\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029411\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029413\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029409\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029414\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029415\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/26/44454?source=related_link\">",
"      Adenosine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/59/14261?source=related_link\">",
"      Adenosine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3445="Brentuximab vedotin: Patient drug information";
var content_f3_23_3445=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Brentuximab vedotin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=see_link\">",
"     see \"Brentuximab vedotin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13204259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adcetris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F16369259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adcetris&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13737688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may rarely cause a very bad brain infection called PML (progressive multifocal leukoencephalopathy). People with a weak immune systems have more chance of getting this infection. Read the part in this leaflet which tells you when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13204060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13204059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516784",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to brentuximab vedotin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13204064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for up to 12 months after this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13204065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever, chills, itching, hives, chest pain or pressure, or shortness of breath when drug is given. Other drugs may be given to avoid these.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698288",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness and tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697920",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Brain infection may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14789819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in the way you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13204062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13204069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16807 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.1.191.153-863D5741FF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3445=[""].join("\n");
var outline_f3_23_3445=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204259\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16369259\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13737688\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204060\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204059\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204064\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204065\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14789819\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204062\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13204069\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/6/16486?source=related_link\">",
"      Brentuximab vedotin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3446="Insulin NPH: Pediatric drug information";
var content_f3_23_3446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin NPH: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"    see \"Insulin NPH: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42868?source=see_link\">",
"    see \"Insulin NPH: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2135494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HumuLIN&reg; N;",
"     </li>",
"     <li>",
"      NovoLIN&reg; N",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2136088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humulin&reg; N;",
"     </li>",
"     <li>",
"      Novolin&reg; ge NPH",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2984311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Insulin",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Intermediate-Acting",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2984342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"      see \"Insulin NPH: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin NPH is an intermediate-acting insulin formulation which is usually administered subcutaneously once or twice daily. When compared to insulin regular, insulin NPH has a slower onset and longer duration of activity. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     . Insulin NPH is",
"     <b>",
"      not",
"     </b>",
"     intended for initial therapy; basal insulin requirements should be established",
"     <b>",
"      first",
"     </b>",
"     to direct dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Augmentation therapy (patients for which diet, exercise, weight reduction, and oral hypoglycemic agents have not been adequate): Adults: SubQ: Initial dosage of 0.2 units/kg/day or 10 units/day of an intermediate-acting (eg, NPH) or long-acting insulin administered at bedtime has been recommended. As an alternative, regular insulin or rapid-acting insulin formulations administered before meals have also been used. Dosage must be carefully adjusted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; N: 100 units/mL (3 mL) [prefilled pen]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HumuLIN&reg; N: 100 units/mL (3 mL, 10 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NovoLIN&reg; N: 100 units/mL (10 mL) [vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2135496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2984343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: SubQ: Gently roll vial or pen in the palms of the hands to resuspend before use; administer into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated. Cold injections should be avoided. Administer within 15 minutes before a meal (before breakfast and supper). May be mixed with regular insulin, insulin aspart, insulin lispro, and insulin glulisine; always add NPH insulin last.",
"     <b>",
"      Not for I.V. administration",
"     </b>",
"     or use in insulin infusion pumps.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2136092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     A universal sterile diluent, Sterile Diluent for Humalog&reg;, Humulin&reg; N, Humulin&reg; R, Humulin&reg; 70/30, and Humulin&reg; R U-500, is available from the manufacturer for SubQ administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Insulin aspart, insulin glulisine, insulin lispro, insulin regular.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Insulin detemir, insulin glargine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2984319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be mixed with regular insulin, insulin lispro, insulin aspart, and insulin glulisine (always add the NPH insulin to the mixture last). A sterile diluent is available from the manufacturer for preparing dilutions of Humulin&reg; N.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humulin&reg; N vials: Store unopened vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored for up to 31 days in the refrigerator between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) or at room temperature &le;30&deg;C (&le;86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humulin&reg; N pens: Store unopened pens in the refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; keep away from heat and sunlight. Once punctured (in use), cartridge/pen should be stored at room temperature 15&deg;C  to 30&deg;C (59&deg;F to 86&deg;F) for up to 14 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Novolin&reg; N: Store unopened vials in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) until product expiration date or at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store vials at room temperature &le;25&deg;C (&le;77&deg;F) for up to 42 days (includes days stored at room temperature for unopened vials, if applicable); refrigeration of in use vials is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2984312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM); type 2 diabetes mellitus (noninsulin dependent, NIDDM) to control hyperglycemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2136087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       HumuLIN&reg; N may be confused with HumuLIN&reg; R, HumaLOG&reg;, Humira&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NovoLIN&reg; N may be confused with NovoLIN&reg; R, NovoLOG&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2135512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2984314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to NPH insulin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution and monitor closely in patient with hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2984315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Hypoglycemia may result from increased work or exercise without eating.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2135518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2135517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2984318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2135504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range. Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2984344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2984345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 30-90 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 70-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control with type 1 diabetes:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;6 years: &le;8.5% and &ge;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 years: &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     13-19 years: &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: &lt;7%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Plasma glucose*:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preprandial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13 years to Adults: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Bedtime and overnight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;6 years: 110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     6-12 years: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     13-19 years: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak postprandial** : Adults: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     *Plasma glucose concentrations are generally 10% to 15% higher than those in whole blood",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     **Peak postprandial plasma glucose is measured 1-2 hours after a meal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2984320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. Insulin NPH is an intermediate-acting form of insulin.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:  6-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 18 to &gt;24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2984341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2984346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42868?source=see_link\">",
"      see \"Insulin NPH: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate-acting (eg, NPH) or long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate-acting (eg, NPH) or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12804 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3446=[""].join("\n");
var outline_f3_23_3446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135494\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136088\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984311\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984342\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104236\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135496\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984343\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136092\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984319\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984312\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2136087\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135512\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984314\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984354\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984315\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135518\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135517\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984318\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2135504\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984344\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984345\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984320\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984355\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984341\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984346\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455399\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12804\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12804|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=related_link\">",
"      Insulin NPH: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/55/42868?source=related_link\">",
"      Insulin NPH: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3447="Definition and diagnosis of mixed connective tissue disease";
var content_f3_23_3447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and diagnosis of mixed connective tissue disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3447/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3447/contributors\">",
"     Robert M Bennett, MD, FRCP, MACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3447/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3447/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3447/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3447/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/23/3447/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed connective tissue disease (MCTD) was originally defined in 1972 as a connective tissue disorder characterized by the presence of high titers of a distinctive autoantibody, now called anti-U1-RNP (previously termed anti-ENA) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/1\">",
"     1",
"    </a>",
"    ]. The central premise of the MCTD concept is that of an overlap syndrome associated with anti-U1-RNP antibodies that incorporates selected clinical features of systemic lupus erythematosus, systemic sclerosis (scleroderma), and polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definitive diagnosis of MCTD is often complicated by the fact that the overlapping features tend to occur sequentially [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/3\">",
"     3",
"    </a>",
"    ]. This confusion arises due to the overlap of the various diffuse connective tissue diseases, as well as to changes in the underlying pathology of the illnesses.",
"   </p>",
"   <p>",
"    The definition and diagnosis of mixed connective tissue disease is reviewed here. The symptoms and the prognosis and treatment of the illness, as well as a detailed discussion of anti-U1 RNP antibodies are each discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19095?source=see_link\">",
"     \"Prognosis and treatment of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"     \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five major diffuse connective tissue diseases (DCTD) exist according to current classification schema: systemic lupus erythematosus (SLE); scleroderma (Scl); polymyositis (PM); dermatomyositis (DM); and rheumatoid arthritis (RA). A sixth disorder, Sj&ouml;gren's syndrome, is commonly associated with each of these diseases, but is called primary Sj&ouml;gren's syndrome when it occurs alone.",
"   </p>",
"   <p>",
"    The classical clinical descriptions of these disorders are well known and most patients with well-differentiated disease are easily recognized. However, the definitive diagnosis of each of these disorders is based upon criteria derived from expert opinion; as such the diagnostic criteria are updated from time to time, depending on the relevance of contemporary research. Physicians, experienced in the clinical presentations of the connective tissue disorder, often note that one DCTD seems to evolve into another over the course of several years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/4\">",
"     4",
"    </a>",
"    ]. This occurs in about 25 percent of patients, who are then said to have an overlap syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive diagnosis of MCTD is often complicated by the fact that the characteristic overlapping features, found in association with high titers of anti-U1-RNP antibody, of SLE, scleroderma, and inflammatory myositis, tend to occur sequentially [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/3\">",
"     3",
"    </a>",
"    ]. Confusion arises due to the overlap of the various diffuse connective tissue diseases (DCTDs), as well as to changes in the underlying pathology of the illnesses.",
"   </p>",
"   <p>",
"    Several years may elapse before the constellation of findings suggests the presence of MCTD. As noted above, many patients with a DCTD present with nondiagnostic features, which are considered to represent an \"undifferentiated\" connective tissue disease (UCTD), before displaying clinical characteristics most consistent with a known disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus the initial diagnostic considerations will be expansive (",
"    <a class=\"graphic graphic_table graphicRef76047 \" href=\"UTD.htm?43/9/44189\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several attempts have been made to standardize the diagnostic criteria for MCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. One study reviewed four sets of diagnostic criteria: Sharp, Alarcon-Segovia, Kasukawa, and Kahn, and concluded that those of Alarcon-Segovia and Kahn were \"best\" [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/12\">",
"     12",
"    </a>",
"    ]. The criteria utilized by Alarcon-Segovia had a sensitivity and specificity of 63 and 86 percent, respectively; this accuracy is comparable to that found with the criteria utilized by Kahn (",
"    <a class=\"graphic graphic_table graphicRef74610 \" href=\"UTD.htm?5/52/5964\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Is MCTD a specific disease?",
"    </span>",
"    &nbsp;&mdash;&nbsp;None of the DCTDs can be defined as a specific disease, if a distinct disease, by definition, requires both unique clinical features and consistent pathology. Each DCTD contains subsets of patients with clinical and pathologic characteristics which differ from other patients with the same diagnosis. After the original description of MCTD in 1972, there initially was controversy as to its place as a \"distinctive\" DCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/2,13\">",
"     2,13",
"    </a>",
"    ], but some 40 years and over 1700 MCTD publications later, there is now a consensus that MCTD should be considered a &ldquo;distinct clinical entity&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the early stages most patients destined to develop MCTD cannot be differentiated from the other classical DCTDs. The early simultaneous presence of overlap features usually seen in SLE, Scl and PM is seldom seen. More commonly the overlapping features occur sequentially over several years. Prominent early symptoms are: easy fatigability, poorly defined myalgias, arthralgias and Raynaud phenomenon. The common diagnostic considerations at this juncture are usually RA, SLE or undifferentiated connective tissue disease (UCTD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/3,15-17\">",
"     3,15-17",
"    </a>",
"    ]. If the patient has swollen hands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    puffy fingers in association with a high titer speckled ANA, they should be carefully followed for the evolution of overlap features. A high titer of anti-RNP antibodies in such a patient is a powerful predictor of a later evolution into MCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Other, less common, early features include: a severe inflammatory myopathy, acute arthritis, aseptic meningitis, transverse myelitis, digital gangrene, high fever, acute abdomen and trigeminal neuropathy, and sensorineural hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/20-25\">",
"     20-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major reason to consider MCTD a distinct clinical entity is that the presence of high titers of anti-U1 RNP antibodies is associated with several distinctive clinical characteristics; for example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with U1 RNP antibodies seldom develop diffuse proliferative glomerulonephritis, psychosis, or seizures; these abnormalities are a major source of morbidity and mortality in SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with U1 RNP antibodies nearly always have an early development of Raynaud phenomenon [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/1,2,28\">",
"       1,2,28",
"      </a>",
"      ] and a nailfold capillary pattern that is the same as in Scl but different from classical SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/29\">",
"       29",
"      </a>",
"      ]. The Raynaud phenomenon only occurs in about 25 percent of patients with classical SLE.",
"     </li>",
"     <li>",
"      Patients with U1 RNP antibodies are more likely to develop pulmonary hypertension than patients with classical SLE or Scl. Pulmonary hypertension is the major cause of death in MCTD [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/30-32\">",
"       30-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with U1 RNP antibodies are more likely than SLE patients to test positively for rheumatoid [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/33,34\">",
"       33,34",
"      </a>",
"      ] or antibodies to cyclic citrullinated peptide (anti-CCP) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/35\">",
"       35",
"      </a>",
"      ], and also more likely to develop an erosive arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/32-34,36\">",
"       32-34,36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the concept of MCTD is useful in defining a subgroup of patients with unique clinical features, treatment profile, and prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms and clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting symptoms in MCTD are often nonspecific such as frequent fatigue, myalgias, arthralgias and low grade fevers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/1,2,36\">",
"     1,2,36",
"    </a>",
"    ] Some patients, however, present acutely with a trigeminal neuropathy, severe polymyositis, acute arthritis, aseptic meningitis, digital gangrene, acute abdomen, or high fever [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Characteristic clinical symptoms of MCTD eventually emerge including Raynaud phenomenon, hand edema, puffy fingers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prominent synovitis. Overlapping clinical features include an inflammatory muscle disease and sclerodactyly. Affected patients are prone to develop pulmonary hypertension and a scleroderma-like vasculopathy, but serious renal or CNS disease is uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the original description of MCTD included circulating autoantibodies directed against ENA (an RNAse sensitive extractable nuclear antigen), now known to be U1 RNP. The presence of this specific antibody still remains a sine qua non for the diagnosis of MCTD.",
"   </p>",
"   <p>",
"    Nevertheless, anti U1 RNP antibodies alone do not guarantee that a patient either has MCTD or will continue to display the MCTD phenotype. As an example, the first clue to the diagnosis of MCTD is often the presence of a positive ANA with a high titer speckled pattern (commonly &gt; 1:1000 and often greater than 1:10,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/41\">",
"     41",
"    </a>",
"    ]. However, antibodies to U1 RNP, Sm, Ro, and La all produce a speckled pattern, and antibodies to double stranded DNA (dsDNA), Sm, and Ro are occasionally seen transiently in patients with MCTD. If dsDNA, Sm, or Ro are the dominant and persistent autoantibody system then the patient is more likely to develop a connective tissue illness other than MCTD. If, on the other hand, antibodies to U1 RNP remain dominant then the patient is likely to continue to have the clinical characteristics of MCTD.",
"   </p>",
"   <p>",
"    There are several hierarchies of antibody response in patients who eventually develop MCTD, with each higher level being associated with an increased expression of the MCTD clinical profile [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level 1 - Positive ANA",
"     </li>",
"     <li>",
"      Level 2 - High titer, speckled ANA pattern",
"     </li>",
"     <li>",
"      Level 3 - Anti-U1 RNP antibodies",
"     </li>",
"     <li>",
"      Level 4 - Anti 68 kD and A' antibodies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    U1 RNP is now known to consist of RNA plus three proteins, A', C, and a 68-70 kD protein. The clinical picture of MCTD most closely correlates with the presence of IgG antibodies to the 68-70 kD and A' proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=see_link\">",
"     \"Anti-U1 RNP antibodies in mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Determinants of overlap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients initially diagnosed with MCTD eventually manifest symptoms more consistent with SLE, while others first diagnosed with SLE may develop an overlap syndrome. One study, for example, followed the clinical course of 46 patients initially diagnosed with MCTD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/48\">",
"     48",
"    </a>",
"    ]. At five year follow-up, eighteen were subsequently re-diagnosed with SLE, seven with scleroderma, three with rheumatoid arthritis, and three with combinations of these disorders.",
"   </p>",
"   <p>",
"    The clinical correlates of MCTD appear to be most closely associated with antibodies to the 68 kD and the A' proteins of the U1 RNP complex. In contrast, antibodies against a 28 to 29 kD protein complex, anti-Sm",
"    <span class=\"nowrap\">",
"     B/B',",
"    </span>",
"    are most closely associated with SLE (particularly serositis) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"     \"Overview of the clinical manifestations of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The typical phenotype may also be in part genetically determined. The following associations have been noted in the diffuse connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HLA-DR3 in SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/51,52\">",
"       51,52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DR5 in scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/53\">",
"       53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      HLA-DR4 or HLA-DR2 in patients with the MCTD overlap phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3447/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23793971\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mixed connective tissue disease (MCTD) is an overlap syndrome including features of systemic lupus erythematosus (SLE), systemic sclerosis (Scl, scleroderma), and polymyositis (PM). It is further defined by the uniform presence of high titers of a distinctive autoantibody, now called anti-U1-RNP (previously termed anti-ENA). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Disease classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of MCTD is often complicated by the sequential occurrence of the characteristic overlapping features, often over several years. The early simultaneous presence of overlap features usually seen in SLE, Scl, and PM is uncommon. There is no single set of diagnostic criteria that is universally accepted. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Is MCTD a specific disease?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The MCTD syndrome defines a cluster of patients with unique clinical features, treatment profile, and prognosis. The presence of high titers of anti-U1 RNP antibodies are associated with the very infrequent development of diffuse proliferative glomerulonephritis, psychosis, or seizures, unlike SLE; with the early development of Raynaud phenomenon in nearly all patients, with a nailfold capillary pattern that is the same as that in Scl but is different from that in classical SLE; with the greater likelihood of developing pulmonary hypertension, the major cause of death in MCTD, than in patients with classical SLE or Scl; and with the greater likelihood of being rheumatoid factor positive and developing an erosive arthritis, compared with SLE. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Is MCTD a specific disease?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presenting symptoms in MCTD are often nonspecific such as fatigue, myalgias, arthralgias, and low grade fevers, although some patients present acutely with a trigeminal neuropathy, severe polymyositis, acute arthritis, aseptic meningitis, digital gangrene, acute abdomen, or high fever. Characteristic clinical symptoms of MCTD eventually emerge including Raynaud phenomenon, hand edema, puffy fingers,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prominent synovitis. Overlapping clinical features include an inflammatory muscle disease and sclerodactyly. Affected patients are prone to develop pulmonary hypertension and a scleroderma-like vasculopathy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Symptoms and clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti U1 RNP antibodies alone do not guarantee that a patient either has MCTD or will continue to display the MCTD phenotype. Antibodies to double stranded DNA (dsDNA), Sm, and Ro are occasionally seen transiently in patients with MCTD. If dsDNA, Sm, or Ro are the dominant and persistent autoantibody system then the patient is more likely to develop a connective tissue illness other than MCTD. The patient is likely to continue to have the clinical characteristics of MCTD if antibodies to U1 RNP remain dominant. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical correlates of MCTD appear to be most closely associated with antibodies to the 68 kD and the A' proteins of the U1 RNP complex. In contrast, antibodies against a 28 to 29 kD protein complex, anti-Sm",
"      <span class=\"nowrap\">",
"       B/B',",
"      </span>",
"      are most closely associated with SLE (particularly serositis). The typical phenotype may also be in part genetically determined. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Determinants of overlap'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/1\">",
"      Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/2\">",
"      Bennett RM, O'Connell DJ. Mixed connective tisssue disease: a clinicopathologic study of 20 cases. Semin Arthritis Rheum 1980; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett RM. Overlap Syndromes. In: Textbook of Rheumatology, 8th, WB Saunders Co, Philadelphia 2009. p.1381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/4\">",
"      Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2003; 21:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/5\">",
"      Maddison PJ. Overlap syndromes and mixed connective tissue disease. Curr Opin Rheumatol 1991; 3:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/6\">",
"      Mosca M, Tani C, Neri C, et al. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/7\">",
"      Jonsson J, Norberg R. Symptomatology and diagnosis in connective tissue disease. II. Evaluations and follow-up examinations in consequence of a speckled antinuclear immunofluorescence pattern. Scand J Rheumatol 1978; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/8\">",
"      Doria A, Ghirardello A, de Zambiasi P, et al. Japanese diagnostic criteria for mixed connective tissue disease in Caucasian patients. J Rheumatol 1992; 19:259.",
"     </a>",
"    </li>",
"    <li>",
"     Kahn MF, Appelboom T. Syndrom de Sharp. In: Les maladies systemiques, 3rd, Kahn MF, Peltier AP, Meyer O, Piette JC (Eds), Flammarion, Paris 1991. p.545.",
"    </li>",
"    <li>",
"     Alarcon Segovia D, Villareal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Kasukawa R, Sharp G (Eds), Elsevier, Amsterdam 1987. p.33.",
"    </li>",
"    <li>",
"     Kasukawa R, Tojo T, Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In: Mixed Connective Tissue Disease and Antinuclear Antibodies, Kasukawa R, Sharp G (Eds), Elsevier, Amsterdam 1987. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/12\">",
"      Alarc&oacute;n-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol 1989; 16:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/13\">",
"      Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am 2005; 31:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/14\">",
"      Cappelli S, Bellando Randone S, Martinovi D, et al. \"To be or not to be,\" ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum 2012; 41:589.",
"     </a>",
"    </li>",
"    <li>",
"     Kashiwazaki S, Kondo H, Fukui T. features of anti-nRNP antibody positive patients. In: Mixed Connective Tissue Disease and Anti-nuclear Antibodies, Kasukawa R, Sharp G (Eds), Elsevier, Amsterdam 1987. p.261.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/16\">",
"      LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/17\">",
"      Bodolay E, Szegedi G. [Undifferentiated connective tissue disease]. Orv Hetil 2009; 150:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/18\">",
"      Lundberg I, Nyman U, Pettersson I, Hedfors E. Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Br J Rheumatol 1992; 31:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/19\">",
"      Greidinger EL, Hoffman RW. Autoantibodies in the pathogenesis of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/20\">",
"      Hojaili B, Barland P. Trigeminal neuralgia as the first manifestation of mixed connective tissue disorder. J Clin Rheumatol 2006; 12:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/21\">",
"      O'Connell DJ, Bennett RM. Mixed connective tissue disease--clinical and radiological aspects of 20 cases. Br J Radiol 1977; 50:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/22\">",
"      Hajas A, Szodoray P, Barath S, et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 2009; 36:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/23\">",
"      Fujita Y, Fujii T, Nakashima R, et al. Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different cases. Mod Rheumatol 2008; 18:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/24\">",
"      Bhinder S, Harbour K, Majithia V. Transverse myelitis, a rare neurological manifestation of mixed connective tissue disease--a case report and a review of literature. Clin Rheumatol 2007; 26:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/25\">",
"      Pope JE. Other manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/26\">",
"      Bennett RM, Spargo BH. Immune complex nephropathy in mixed connective tissue disease. Am J Med 1977; 63:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/27\">",
"      Kitridou RC, Akmal M, Turkel SB, et al. Renal involvement in mixed connective tissue disease: a longitudinal clinicopathologic study. Semin Arthritis Rheum 1986; 16:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/28\">",
"      Lambova SN, Kuzmanova SI. Raynaud's phenomenon in common rheumatic diseases. Folia Med (Plovdiv) 2006; 48:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/29\">",
"      Peller JS, Gabor GT, Porter JM, Bennett RM. Angiographic findings in mixed connective tissue disease. Correlation with fingernail capillary photomicroscopy and digital photoplethysmography findings. Arthritis Rheum 1985; 28:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/30\">",
"      Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med 2009; 30:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/31\">",
"      Bull TM, Fagan KA, Badesch DB. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/32\">",
"      Lundberg IE. The prognosis of mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/33\">",
"      Bennett RM, O'Connell DJ. The arthritis of mixed connective tissue disease. Ann Rheum Dis 1978; 37:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/34\">",
"      Mimura Y, Ihn H, Jinnin M, et al. Rheumatoid factor isotypes in mixed connective tissue disease. Clin Rheumatol 2006; 25:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/35\">",
"      Yin G, Cen XM, Yang M, Xie QB. [Detecting anti-cyclic citrullinated peptide antibody in patients with connective tissue diseases]. Sichuan Da Xue Xue Bao Yi Xue Ban 2011; 42:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/36\">",
"      Maddison PJ, Mogavero H, Reichlin M. Patterns of clinical disease associated with antibodies to nuclear ribonucleoprotein. J Rheumatol 1978; 5:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/37\">",
"      Bennett RM, Bong DM, Spargo BH. Neuropsychiatric problems in mixed connective tissue disease. Am J Med 1978; 65:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/38\">",
"      Bennett RM, O'Connell DJ. Gastrointestinal systemic sclerosis in mixed connective tissue disease. Arthritis Rheum 1979; 22:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/39\">",
"      Hagen NA, Stevens JC, Michet CJ Jr. Trigeminal sensory neuropathy associated with connective tissue diseases. Neurology 1990; 40:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/40\">",
"      Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med 1976; 295:1149.",
"     </a>",
"    </li>",
"    <li>",
"     Bennett RM. Mixed connective tissue disease and other overlap syndromes. In: Textbook of Rheumatology, 7th, Kelley W, Harris EDJ, Ruddy SH, Sledge G (Eds), WB Saunders, Philadelphia 2004. p.1241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/42\">",
"      Greidinger EL, Hoffman RW. The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'/B proteins as predominant U1 RNP immunogens. Arthritis Rheum 2001; 44:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/43\">",
"      Rettenmaier LJ, Sharp GC, Takeda Y, et al. U1-68KD-positive mixed connective tissue disease appears genetically distinct, within HLA from systemic lupus erythematosus. Arthritis Rheum 1989; 32:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/44\">",
"      Netter HJ, Guldner HH, Szostecki C, Will H. Major autoantigenic sites of the (U1) small nuclear ribonucleoprotein-specific 68-kDa protein. Scand J Immunol 1990; 32:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/45\">",
"      McHugh N, James I, Maddison P. Clinical significance of antibodies to a 68 kDa U1RNP polypeptide in connective tissue disease. J Rheumatol 1990; 17:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/46\">",
"      Margaux J, Hayem G, Palazzo E, et al. Clinical usefulness of antibodies to U1snRNP proteins in mixed connective tissue disease and systemic lupus erythematosus. Rev Rhum Engl Ed 1998; 65:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/47\">",
"      Hoffman RW, Rettenmaier LJ, Takeda Y, et al. Human autoantibodies against the 70-kd polypeptide of U1 small nuclear RNP are associated with HLA-DR4 among connective tissue disease patients. Arthritis Rheum 1990; 33:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/48\">",
"      van den Hoogen FH, Spronk PE, Boerbooms AM, et al. Long-term follow-up of 46 patients with anti-(U1)snRNP antibodies. Br J Rheumatol 1994; 33:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/49\">",
"      Lundberg I, Hedfors E. Clinical course of patients with anti-RNP antibodies. A prospective study of 32 patients. J Rheumatol 1991; 18:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/50\">",
"      Gendi NS, Welsh KI, Van Venrooij WJ, et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic followup of 46 patients. Arthritis Rheum 1995; 38:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/51\">",
"      Alexander EL, McNicholl J, Watson RM, et al. The immunogenetic relationship between anti-Ro(SS-A)/La(SS-B) antibody positive Sj&ouml;gren's/lupus erythematosus overlap syndrome and the neonatal lupus syndrome. J Invest Dermatol 1989; 93:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/52\">",
"      Ruuska P, H&auml;meenkorpi R, Forsberg S, et al. Differences in HLA antigens between patients with mixed connective tissue disease and systemic lupus erythematosus. Ann Rheum Dis 1992; 51:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/53\">",
"      Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995; 12:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/54\">",
"      Genth E, Zarnowski H, Mierau R, et al. HLA-DR4 and Gm(1,3;5,21) are associated with U1-nRNP antibody positive connective tissue disease. Ann Rheum Dis 1987; 46:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3447/abstract/55\">",
"      Kuwana M, Okano Y, Kaburaki J, Inoko H. Clinical correlations with HLA type in Japanese patients with connective tissue disease and anti-U1 small nuclear RNP antibodies. Arthritis Rheum 1996; 39:938.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7541 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3447=[""].join("\n");
var outline_f3_23_3447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23793971\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Is MCTD a specific disease?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms and clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Determinants of overlap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23793971\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7541\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7541|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/9/44189\" title=\"table 1\">",
"      Algorithm dx UCTD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/52/5964\" title=\"table 2\">",
"      Est dx MCTD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2743?source=related_link\">",
"      Anti-U1 RNP antibodies in mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=related_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/41/19095?source=related_link\">",
"      Prognosis and treatment of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3448="Pharmacologic therapy in survivors of sudden cardiac arrest";
var content_f3_23_3448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic therapy in survivors of sudden cardiac arrest",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Jie Cheng, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3448/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/23/3448/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden cardiac arrest (SCA) and sudden cardiac death (SCD) refer to the sudden cessation of cardiac activity with hemodynamic collapse, typically due to sustained ventricular tachycardia or ventricular fibrillation. These events mostly occur in patients with structural heart disease (that may not have been previously diagnosed), particularly coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=see_link\">",
"     \"Pathophysiology and etiology of sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The event is referred to as SCA (or aborted SCD) if an intervention (eg, defibrillation) or spontaneous reversion restores circulation. The event is called SCD if the patient dies. However, the use of SCD to describe both fatal and nonfatal cardiac arrest often persists by convention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of SCA consists of acute resuscitation followed, in survivors, by therapy to prevent recurrence. Patients with ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation not due to a reversible cause generally receive an implantable cardioverter-defibrillator (ICD). Antiarrhythmic drugs are used in select patients as adjunctive therapy, or as primary therapy when an ICD is not indicated or refused by the patient.",
"   </p>",
"   <p>",
"    This topic will review the role of pharmacologic therapy in survivors of SCA, with an emphasis on the role of antiarrhythmic drugs. Issues related to the acute management of SCA, the evaluation of survivors, and the utility of an ICD, arrhythmic surgery or radiofrequency ablation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=see_link\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109254618\">",
"    <span class=\"h1\">",
"     ANTIARRHYTHMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic therapy, in the form of beta blockers and antiarrhythmic medications, can be helpful in controlling arrhythmias in survivors of sudden cardiac arrest (SCA). However, due to the efficacy of the implantable cardioverter-defibrillator (ICD) in treating sustained ventricular tachyarrhythmias and improving mortality, antiarrhythmic drugs are generally reserved for use in select patients as adjunctive therapy, or as primary therapy when an ICD is not indicated or refused by the patient. (See",
"    <a class=\"local\" href=\"#H7000260\">",
"     'ICD therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Empiric pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric antiarrhythmic drug therapy, primarily with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or beta blockers, is an effective approach for survivors of SCA who have refused ICD placement or are not candidates for an ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among antiarrhythmic medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is the most effective for preventing recurrent ventricular tachyarrhythmias. Empiric therapy with amiodarone is an effective approach to the management of survivors of SCA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, amiodarone is the antiarrhythmic drug of choice for patients with significant left ventricular dysfunction, since it does not exacerbate heart failure and is less proarrhythmic than other agents [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The CASCADE trial randomly assigned 228 survivors of out-of-hospital ventricular fibrillation not due to a myocardial infarction to empiric therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or with other antiarrhythmic drugs guided by EP testing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/5\">",
"     5",
"    </a>",
"    ]. Two major findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival free of cardiac death, resuscitated cardiac arrest, or defibrillator shocks for syncope was significantly higher with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      than with EP-guided antiarrhythmic therapy (82 versus 69 percent at two years, and 53 versus 40 percent at six years) (",
"      <a class=\"graphic graphic_figure graphicRef60700 \" href=\"UTD.htm?16/42/17069\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients receiving an ICD along with drug therapy, survival free from a shock was significantly higher in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      than in those receiving other antiarrhythmic agents (94 versus 78 percent at three years). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers reduce the incidence of sudden death and total mortality in patients with a recent myocardial infarction and in those with symptomatic heart failure or congenital long QT syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link\">",
"     \"Prognosis and management of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although beta blockers are not a first-line drug for patients presenting with symptomatic ventricular tachycardia (VT) or ventricular fibrillation (VF), they may be effective when no specific antiarrhythmic treatment is given. In an analysis from the AVID trial, patients who were discharged from the hospital on a beta blocker had a mortality reduction compared to those patients not receiving a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7000483\">",
"    <span class=\"h2\">",
"     Guided pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, it was proposed that the choice of antiarrhythmic drug should be guided by objective criteria based upon either noninvasive (ambulatory [Holter] monitoring) or invasive testing (electrophysiologic [EP] testing). An effective drug, identified by either technique, was noted to prevent recurrent arrhythmia and potential improve survival compared to no therapy or an ineffective drug (",
"    <a class=\"graphic graphic_figure graphicRef57256 \" href=\"UTD.htm?10/61/11230\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66798 \" href=\"UTD.htm?24/29/25054\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. In current practice, however, when pharmacologic therapy is required due to ongoing arrhythmias in a patient with an ICD or in a patient who has refused ICD placement or is not a candidate for an ICD, empiric treatment with beta blockers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is the preferred approach. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Amiodarone'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Adjunctive therapy in patients with an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because an implantable cardioverter-defibrillator (ICD) does not prevent arrhythmias, patients who have arrhythmias with symptoms or device discharges may require adjunctive antiarrhythmic therapy. Class III antiarrhythmic drugs, in particular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , are most commonly used as adjunctive therapy with an ICD (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main indications for concomitant antiarrhythmic drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To reduce the frequency of ventricular arrhythmias in patients with frequent ICD shocks. In one analysis, the occurrence of frequent ICD shocks was the primary reason for adding an antiarrhythmic drug (64 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To suppress other arrhythmias that cause symptoms or interfere with ICD function (eg, causing \"inappropriate\" shocks). Inappropriate shocks occur in up to 29 percent of ICD patients and can have a substantial impact on the patient&rsquo;s quality of life [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/18\">",
"       18",
"      </a>",
"      ]. These shocks are caused by a variety of arrhythmias including sinus tachycardia, atrial fibrillation, and nonsustained ventricular tachycardia (NSVT) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link&amp;anchor=H17#H17\">",
"       \"Implantable cardioverter-defibrillators: Complications\", section on 'Inappropriate shocks'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To reduce the ventricular rate of VT so that it is better tolerated hemodynamically and more amenable to termination by anti-tachycardia pacing or low energy cardioversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although antiarrhythmic drugs may be used for these reasons, more sophisticated programming features of current generation ICDs may allow the device to ignore clinically unimportant and non-life-threatening arrhythmias rather than delivering an unnecessary shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H13#H13\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'ICD programming and therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials and a systematic review have evaluated the efficacy of antiarrhythmic drugs as adjuvant therapy in ICD patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. There were significant differences in trial methodologies, which limit direct comparisons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2098809\">",
"    <span class=\"h4\">",
"     OPTIC trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The OPTIC trial, which was included in the systematic review, compared the relative efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , and beta blockers that do not exhibit class III antiarrhythmic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/20\">",
"     20",
"    </a>",
"    ]. In this multicenter trial, 412 patients with an implantable cardioverter-defibrillator (ICD) were treated with a beta blocker alone, a beta blocker plus amiodarone, or sotalol alone. At one year, the rate of any ICD shock was significantly lower with amiodarone plus a beta blocker than with sotalol or a beta blocker alone (10.3 versus 24.3 and 38.5 percent, respectively). There was a trend toward fewer total ICD shocks in the sotalol group compared to beta blockers alone; however, sotalol had no significant effect compared to a beta blocker alone in reducing the incidence of appropriate shocks or antitachycardia pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Systematic reviews",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two systematic reviews have assessed the efficacy and safety of a variety of antiarrhythmic drugs for preventing ICD therapies as well as the impact of antiarrhythmic therapy on shock reduction and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In one review which included eight randomized trials involving 1889 patients, there was significant heterogeneity among the trials, including variation on the active therapy, control therapy, and outcomes assessed, and the results were divided into those trials that compared class III antiarrhythmic drugs (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ) with beta blockers, and those trials that compared class III drugs (sotalol,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      , and azimilide) with placebo or no antiarrhythmic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/24\">",
"       24",
"      </a>",
"      ]. The outcomes reported in each of the individual trials included reduction in total shocks, reduction in appropriate shocks, reduction in inappropriate shocks, and reduction in all ICD therapies (eg, including antitachycardia pacing), and the following findings were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      in combination with a beta blocker significantly reduced the incidence of shocks compared to beta blocker alone (hazard ratio [HR] 0.27, 95% CI 0.14 to 0.52). These results were largely driven by the OPTIC trial.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      reduced the incidence of ICD shocks when compared to placebo (HR 0.55, 95% CI 0.4 to 0.78). There was also a trend toward fewer shocks in patients treated with sotalol versus another beta blocker.",
"     </li>",
"     <li>",
"      Treatment with either azimilide or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      resulted in nonsignificant trends towards reduction in total ICD shocks compared to placebo. However, the incidence of appropriate ICD therapies (shocks plus antitachycardia pacing) was significantly reduced by azimilide (HR 0.31, 95% CI 0.29 to 0.34).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a second systematic review of 17 randomized trials involving 5875 patients, patients taking an antiarrhythmic drug had significantly fewer ICD shocks compared with those not on an antiarrhythmic (odds ratio [OR] 0.59, 95% CI 0.36-0.96) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/25\">",
"       25",
"      </a>",
"      ]. However, the reduction in shocks seen in patients receiving an antiarrhythmic drug was not associated with improved survival (OR 1.07, 95% CI 0.72-1.59).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, despite the heterogeneity of treatments, control therapies, and outcomes assessed in different studies, antiarrhythmic drugs (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ) are effective for reducing total ICD shocks but seem to have no impact on survival among patients with an ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs may have an adverse effect on ICD defibrillation thresholds and, by slowing the tachycardia rate, may preclude recognition of the arrhythmia by the ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    , and particularly its major metabolite desethylamiodarone, increases the defibrillation threshold in a dose-dependent fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. These potential problems mandate reevaluation of defibrillation thresholds and tachycardia response whenever an antiarrhythmic drug is added, its dose changed, or a condition supervenes that is likely to alter the pharmacokinetics or pharmacodynamics of a drug in use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=see_link&amp;anchor=H9#H9\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\", section on 'DFT testing after the initiation of antiarrhythmic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potential problem with antiarrhythmic drugs is the propensity for proarrhythmia due to prolongation of the QT interval. One advantage of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is a very low frequency of proarrhythmia. Although amiodarone can markedly prolong the QT interval, torsades de pointes is rare. However, caution is necessary when amiodarone is given with other drugs that can prolong the QT interval or therapy is complicated by hypokalemia or hypomagnesemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7000260\">",
"    <span class=\"h1\">",
"     ICD THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who survive sudden cardiac arrest caused by ventricular",
"    <span class=\"nowrap\">",
"     tachycardia/ventricular",
"    </span>",
"    fibrillation not due to a reversible cause generally receive an implantable cardioverter-defibrillator (ICD). A meta-analysis of three major ICD trials &mdash; CASH, CIDS, and, AVID &mdash; found a 25 percent reduction in overall mortality with an ICD compared to antiarrhythmic therapy (hazard ratio 0.75, 95% CI 0.64 to 0.87) that was entirely due to a 50 percent reduction in sudden death (hazard ratio 0.50, 95% CI 0.34-0.62) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/32\">",
"     32",
"    </a>",
"    ]. The absolute reduction in all-cause mortality was 7 percent, meaning that 15 patients needed to be treated to prevent one death. An additional finding in a second meta-analysis was that the mortality benefit was limited to patients with a left ventricular ejection fraction (LVEF) &le;35 percent; there was little or no benefit when the LVEF was greater than 35 percent (",
"    <a class=\"graphic graphic_figure graphicRef67116 \" href=\"UTD.htm?27/34/28206\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/33\">",
"     33",
"    </a>",
"    ]. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based in part upon these findings, the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (ACC/AHA/HRS)",
"    </span>",
"    device guidelines included a strong recommendation for ICD use in survivors of SCA that was not due to a transient or reversible cause [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/34\">",
"     34",
"    </a>",
"    ]. Similarly, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/European",
"    </span>",
"    Society of Cardiology (ESC) guidelines included strong recommendations for ICD use in survivors of SCA with a variety of underlying disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2100326\">",
"    <span class=\"h1\">",
"     LIPID-LOWERING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive evidence supports the value of lipid-lowering in patients with coronary heart disease (CHD) and as primary prevention in selected patients. The clinical trials that have been performed have not specifically reported the effects on sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lipid-lowering therapy may reduce the rate of recurrent ventricular tachyarrhythmias in patients with an implantable cardioverter-defibrillator (ICD) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This was best illustrated in a retrospective analysis from the AVID trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/36\">",
"     36",
"    </a>",
"    ]. Among 362 patients with CHD who received an ICD, 83 were treated with early and consistent lipid-lowering therapy at the discretion of the treating clinician. There was a significant reduction in the risk of recurrent of ventricular tachycardia or ventricular fibrillation in patients receiving lipid-lowering therapy (adjusted HR 0.40, 95% CI 0.15 to 0.58). These observations suggest that part of the benefit of lipid-lowering therapy may be from an antiarrhythmic effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are mixed data on whether the administration of fish oil reduces the risk of recurrent ventricular tachyarrhythmias. A meta-analysis of three fish oil trials showed no overall effect of fish oil treatment on the risk of ICD discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H19#H19\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Recurrent ventricular tachyarrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because of the survival benefit associated with an implantable cardioverter-defibrillator (ICD) compared with antiarrhythmic therapy alone, most survivors of sudden cardiac arrest (SCA) due to ventricular tachycardia (VT) or ventricular fibrillation (VF) not associated with a reversible cause should receive an ICD. Antiarrhythmic drugs can be considered as the primary therapy when an ICD is not indicated or refused by the patient. (See",
"      <a class=\"local\" href=\"#H7000260\">",
"       'ICD therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For survivors of SCA due to VT or VF not associated with a reversible cause who are not candidates for or who refuse ICD placement, we recommend the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      rather than other antiarrhythmic drug therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Beta-blockers administered for other indications (ie, post-myocardial infarction) may provide additional antiarrhythmic benefits. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Empiric pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because an ICD does not prevent arrhythmias, patients who have arrhythmias with symptoms or device discharges may require adjunctive antiarrhythmic therapy. The three main indications for concomitant antiarrhythmic drug therapy are [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3448/abstract/15-17\">",
"       15-17",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      To reduce the frequency of ventricular arrhythmias in patients with frequent ICD shocks.",
"     </li>",
"     <li>",
"      To suppress other arrhythmias that cause symptoms or interfere with ICD function (eg, causing \"inappropriate\" shocks).",
"     </li>",
"     <li>",
"      To reduce the ventricular rate of ventricular tachycardia so that it is better tolerated hemodynamically and more amenable to termination by anti-tachycardia pacing or low energy cardioversion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with an ICD who require adjunctive antiarrhythmic therapy due to ongoing arrhythmias, we recommend treatment with the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      plus a beta blocker rather than treatment with amiodarone alone or other antiarrhythmic agents (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This approach is especially preferred in patients with significant left ventricular dysfunction who require adjunctive antiarrhythmic therapy since amiodarone does not exacerbate heart failure and is less proarrhythmic than other agents. (See",
"      <a class=\"local\" href=\"#H109254618\">",
"       'Antiarrhythmic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with an ICD who require adjunctive antiarrhythmic therapy due to ongoing arrhythmias, but who do not otherwise have an indication for treatment with a beta blocker, we suggest treatment with the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      plus a beta blocker rather than treatment with amiodarone alone or other antiarrhythmic agents (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H109254618\">",
"       'Antiarrhythmic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects related to antiarrhythmic medications include proarrhythmia due to prolongation of the QT interval, increased defibrillation thresholds, and slowing of the tachycardia rate, which may preclude its recognition by the ICD. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lipid-lowering therapy administered for other indications may reduce the rate of recurrent ventricular tachyarrhythmias in patients with an implantable cardioverter-defibrillator (ICD). (See",
"      <a class=\"local\" href=\"#H2100326\">",
"       'Lipid-lowering'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/1\">",
"      Weinberg BA, Miles WM, Klein LS, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J 1993; 125:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/2\">",
"      Podrid PJ, Lampert S, Graboys TB, et al. Aggravation of arrhythmia by antiarrhythmic drugs--incidence and predictors. Am J Cardiol 1987; 59:38E.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/3\">",
"      Ravid S, Podrid PJ, Lampert S, Lown B. Congestive heart failure induced by six of the newer antiarrhythmic drugs. J Am Coll Cardiol 1989; 14:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/4\">",
"      Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol 1992; 69:82G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/5\">",
"      Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol 1993; 72:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/6\">",
"      Exner DV, Reiffel JA, Epstein AE, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 1999; 34:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/7\">",
"      Kim SG. The management of patients with life-threatening ventricular tachyarrhythmias: programmed stimulation or Holter monitoring (either or both)? Circulation 1987; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/8\">",
"      Wilber DJ, Garan H, Finkelstein D, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med 1988; 318:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/9\">",
"      Graboys TB, Lown B, Podrid PJ, DeSilva R. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982; 50:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/10\">",
"      Lampert S, Lown B, Graboys TB, et al. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease. Am J Cardiol 1988; 61:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/11\">",
"      Vlay SC, Kallman CH, Reid PR. Prognostic assessment of survivors of ventricular tachycardia and ventricular fibrillation with ambulatory monitoring. Am J Cardiol 1984; 54:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/12\">",
"      Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/13\">",
"      Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/14\">",
"      Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 1983; 308:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/15\">",
"      Knilans TK, Prystowsky EN. Antiarrhythmic drug therapy in the management of cardiac arrest survivors. Circulation 1992; 85:I118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/16\">",
"      Manz M, Jung W, L&uuml;deritz B. Interactions between drugs and devices: experimental and clinical studies. Am Heart J 1994; 127:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/17\">",
"      Steinberg JS, Martins J, Sadanandan S, et al. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study. Am Heart J 2001; 142:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/18\">",
"      Nanthakumar K, Paquette M, Newman D, et al. Inappropriate therapy from atrial fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. Am Heart J 2000; 139:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/19\">",
"      Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/20\">",
"      Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/21\">",
"      Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004; 110:3646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/22\">",
"      Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004; 43:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/23\">",
"      K&uuml;hlkamp V, Mewis C, Mermi J, et al. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol 1999; 33:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/24\">",
"      Ferreira-Gonz&aacute;lez I, Dos-Subir&aacute; L, Guyatt GH. Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review. Eur Heart J 2007; 28:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/25\">",
"      Ha AH, Ham I, Nair GM, et al. Implantable cardioverter-defibrillator shock prevention does not reduce mortality: a systemic review. Heart Rhythm 2012; 9:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/26\">",
"      Jung W, Manz M, L&uuml;deritz B. Effects of antiarrhythmic drugs on defibrillation threshold in patients with the implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1992; 15:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/27\">",
"      Mann DE, Kelly PA, Damle RS, Reiter MJ. Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming. Pacing Clin Electrophysiol 1994; 17:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/28\">",
"      Goldschlager N, Epstein A, Friedman P, et al. Environmental and drug effects on patients with pacemakers and implantable cardioverter/defibrillators: a practical guide to patient treatment. Arch Intern Med 2001; 161:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/29\">",
"      Zhou L, Chen BP, Kluger J, et al. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol 1998; 31:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/30\">",
"      Pelosi F Jr, Oral H, Kim MH, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/31\">",
"      Nielsen TD, Hamdan MH, Kowal RC, et al. Effect of acute amiodarone loading on energy requirements for biphasic ventricular defibrillation. Am J Cardiol 2001; 88:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/32\">",
"      Lee DS, Green LD, Liu PP, et al. Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis. J Am Coll Cardiol 2003; 41:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/33\">",
"      Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/34\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/35\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/36\">",
"      Mitchell LB, Powell JL, Gillis AM, et al. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J Am Coll Cardiol 2003; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/37\">",
"      De Sutter J, Tavernier R, De Buyzere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000; 36:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3448/abstract/38\">",
"      Jenkins DJ, Josse AR, Beyene J, et al. Fish-oil supplementation in patients with implantable cardioverter defibrillators: a meta-analysis. CMAJ 2008; 178:157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 972 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.14-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3448=[""].join("\n");
var outline_f3_23_3448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109254618\">",
"      ANTIARRHYTHMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Empiric pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7000483\">",
"      Guided pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Adjunctive therapy in patients with an ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2098809\">",
"      OPTIC trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systematic reviews",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7000260\">",
"      ICD THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2100326\">",
"      LIPID-LOWERING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/972|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17069\" title=\"figure 1\">",
"      Amiodarone in SCD survivors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/61/11230\" title=\"figure 2\">",
"      Efficacy Holter guided therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/29/25054\" title=\"figure 3\">",
"      Efficacy of EP guided therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/34/28206\" title=\"figure 4\">",
"      Meta analysis ICD v amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30599?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39672?source=related_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/54/16233?source=related_link\">",
"      Pathophysiology and etiology of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3449="Nipple discharge";
var content_f3_23_3449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nipple discharge",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Mehra Golshan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Dirk Iglehart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/23/3449/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/23/3449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple discharge is the one of the most commonly encountered breast complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 50 to 80 percent of women in their reproductive years can express one or more drops of fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] and 6.8 percent of women referred to a surgeon because of symptoms of a breast disorder have nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/4\">",
"     4",
"    </a>",
"    ]. Most nipple discharge is of benign origin.",
"   </p>",
"   <p>",
"    The primary goals of evaluation and management are to differentiate patients with benign nipple discharge from those who have an underlying papilloma, cancer, or high-risk lesion, and to manage patients with underlying pathologic nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Isolated papillomas are usually benign, but can harbor areas of atypia or ductal carcinoma in situ (DCIS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical history is most helpful in distinguishing benign from suspicious or pathologic nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/7\">",
"     7",
"    </a>",
"    ]. Benign nipple discharge is usually bilateral, multiductal, and occurs with breast manipulation. Conversely, the risk of cancer is higher when the discharge is spontaneous, bloody or guaiac positive, unilateral, uniductal, associated with a breast mass,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occurs in a woman over 40 years of age.",
"   </p>",
"   <p>",
"    The types of nipple discharge and how to evaluate and manage this common problem will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF NIPPLE DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple discharge is categorized as normal milk production (lactation), physiologic nipple discharge, or pathologic (suspicious) based on the characteristics of presentation. Each category is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal secretory products of the breast are milk and colostrum. During pregnancy and the postpartum period, the mammary glands develop and produce milk in response to a number of physical and biochemical forces [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Milk secretion can continue for at least six months after delivery or after cessation of breastfeeding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=see_link\">",
"     \"Physiology of lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bloody or guaiac positive nipple discharge can be seen in 20 percent of women during the second or third trimester of pregnancy and lactation, and is usually benign. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Grossly bloody discharge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physiologic nipple discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic nipple discharge or galactorrhea is defined as non-pathologic nipple discharge unrelated to pregnancy or breast-feeding. Galactorrhea is usually manifested as bilateral milky nipple discharge involving multiple ducts. The nipple discharge, although usually bilateral and white or clear, may also be unilateral and a variety of colors, including yellow (straw-colored), green, brown, or gray.",
"   </p>",
"   <p>",
"    Galactorrhea is frequently caused by hyperprolactinemia, which may be secondary to medications, endocrine tumors (pituitary adenoma), endocrine abnormalities, or a variety of medical conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Medication related causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic agents are a common cause of galactorrhea. The types of medications implicated include those that cause lactotroph stimulation or inhibit dopamine (",
"    <a class=\"graphic graphic_table graphicRef75914 \" href=\"UTD.htm?2/58/2988\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neurogenic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurogenic stimulation represses the secretion of hypothalamic prolactin inhibitory factor, resulting in hyperprolactinemia and galactorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/10\">",
"     10",
"    </a>",
"    ]. Examples of neurogenic stimulation include chronic breast stimulation from manipulation or clothing (for example, a poorly fitting brassiere).",
"   </p>",
"   <p>",
"    Postthoracotomy syndrome is an unusual disorder in which the healing chest wound simulates the effect of a suckling infant. It can be associated with an elevated prolactin concentration, breast pain, and milk production. A similar effect can be seen with other forms of chest wall injury, including burns [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/11\">",
"     11",
"    </a>",
"    ], cervical spine lesions, and herpes zoster. Often women will see a drop or two of discharge associated with a warm bath or shower. Discharge due to neurogenic stimulation generally resolves with resolution of the inciting factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of stimuli can result in physiologic nipple discharge. In most cases, these stimuli cause hyperprolactinemia. In addition, any disease in or near the hypothalamus or pituitary that interferes with secretion of dopamine or its delivery to the hypothalamus can cause hyperprolactinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stresses such as trauma, surgical procedures, and anesthesia may also inhibit dopamine release, thereby causing hyperprolactinemia and inducing galactorrhea.",
"     </li>",
"     <li>",
"      Purulent nipple discharge can be seen in association with periductal mastitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=see_link&amp;anchor=H10#H10\">",
"       \"Erythematous disorders of the breast\", section on 'Periductal mastitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathologic (suspicious) nipple discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secretory production of fluids other than milk may be due to a pathological process in the breast. The discharge is usually unilateral and localized to a single duct, persistent, and spontaneous. It can be serous (clear or yellow), sanguinous (bloody), or serosanguineous (blood-tinged).",
"   </p>",
"   <p>",
"    The most common cause of pathologic nipple discharge is a papilloma (52 to 57 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/6,12-15\">",
"     6,12-15",
"    </a>",
"    ]. A papilloma is a papillary tumor growing from the lining of the breast duct. The discharge associated with a papilloma can be clear or grossly bloody. Solitary papillomas can harbor areas of atypia or ductal carcinoma in situ (DCIS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of benign breast disease\", section on 'Atypical hyperplasia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard recommendation for management of papillomas is that they be excised whenever they are diagnosed by core needle biopsy, although there is some debate in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. The remaining cases are caused by ductal ectasia or other benign changes (14 to 32 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of benign breast disease\", section on 'Proliferative breast lesions without atypia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignancy is found in 5 to 15 percent of cases of pathologic nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The most common malignancy associated with nipple discharge in the absence of other findings is DCIS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age is predictive of the risk of cancer in women with nipple discharge. In one series of women with isolated nipple discharge, malignancy was present in 3 percent of those &lt;40 years of age, 10 percent of those 40 to 60 years of age, and 32 percent of those over 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and physical examination should be performed in all women with nonlactational nipple discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete medical history, including medication use, should be obtained. Specific areas to address are the appearance of the discharge, whether the discharge is spontaneous or provoked by manipulation of the breast and whether it is unilateral or bilateral. Cancers generally present with spontaneous unilateral, uniductal, frankly bloody or hemoccult positive discharge. Bilateral nipple discharge is usually due to an endocrinologic or physiologic process, although bilateral synchronous cancers can occur. A history of recent trauma should also be elicited. Trauma can include mammographic imaging with compression as well as vigorous manipulation of the nipple by the patient or her partner.",
"   </p>",
"   <p>",
"    Recent onset of amenorrhea or other symptoms of hypogonadism (hot flashes, vaginal dryness) should prompt consideration of hyperprolactinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete breast examination should be performed. The four breast quadrants, subareolar areas, axillae, supraclavicular, and infraclavicular areas should be systematically examined with the woman both lying and sitting with her hands on her hips and then above her head. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H14#H14\">",
"     \"Breast masses and other common breast problems\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The physical examination should include checking for a chiasmal syndrome (eg, bitemporal field loss) and signs of hypothyroidism or hypogonadism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific goals of the examination are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detect skin changes noting the symmetry and contour of the breasts, position of the nipples, scars, and vascular pattern as well as any evidence of skin retraction, dimpling, edema or erythema, ulceration or crusting of the nipple, and changes in skin color",
"     </li>",
"     <li>",
"      Elicit discharge from a nipple and identify the involved duct or ducts. Pressure in a clockwise fashion around the areola can help identify a specific site or duct that is producing the discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Test any discharge for blood with a hemoccult test",
"     </li>",
"     <li>",
"      Detect enlarged axillary or supraclavicular lymph nodes",
"     </li>",
"     <li>",
"      Delineate and document breast masses",
"     </li>",
"     <li>",
"      Identify localized areas of tenderness and relate them to areas of pain noted by the woman and to other physical findings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In particular, the skin covering the breast and nipple areolar complex should be examined for lesions that may be staining the woman's clothes and mimicking nipple discharge. Some examples are Paget disease, insect bites, local infections, and eczema.",
"   </p>",
"   <p>",
"    A warm compress placed on the breasts will enhance the chances of detecting mammary secretion. Gentle, firm pressure should be applied at the base of the areola (not on the nipple), at the site where the newborn's mouth is normally applied. Massage from the periphery towards the nipple areolar complex may also help.",
"   </p>",
"   <p>",
"    It is important to observe whether the discharge comes from one or more ducts on the nipple; flow from one duct is more worrisome than that from multiple ducts. A good light and magnifying lens can help with this identification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bilateral discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral discharge should be evaluated for gross blood or guaiac positivity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guaiac positive nipple discharge, an abnormal mammogram or breast ultrasound, or the presence of a breast mass on physical examination requires evaluation by a surgeon. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"       \"Breast masses and other common breast problems\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"       \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bilateral multiductal secretion that tests negative for blood on the guaiac card is usually normal regardless of color (eg, milky, brown, green, yellow, blue, gray, or clear). Medical evaluation and endocrine workup may be required but surgical intervention is usually not indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Unilateral discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uniductal unilateral discharge is more likely to represent underlying pathology, such as papilloma or intraductal breast carcinoma. This is true even if the discharge is guaiac negative, as the sensitivity of guaiac testing has been shown to be only about 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, multiductal discharge, even if unilateral, is less likely to represent significant breast disease, and should be investigated similarly to bilateral discharge. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Bilateral discharge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The color of nipple discharge can provide an indicator of the risk of underlying malignancy. A meta-analysis of eight studies including 3110 patients showed that patients with bloody nipple discharge had a higher risk of breast cancer (52 percent) than patients with non-bloody nipple discharge (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Straw-colored or clear transparent discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Straw-colored (yellow) or clear (serous) nipple discharge is typically due to a papilloma, but may be associated with a malignancy. The muscular arteries that run through the peduncle of an intraductal papilloma supply adequate blood flow to the neoplasm, but the lymphatics and veins are compromised in the narrow peduncle. The resulting increase in vascular pressure causes a transudate to form in the duct. This discharge is typically a straw-colored, transparent, sticky fluid. It is very much like plasma, since that is the source of the secretion. Unilateral spontaneous serous discharge is considered suspicious and requires a full workup. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathologic (suspicious) nipple discharge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Grossly bloody discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grossly bloody or sanguinous nipple discharge simply means that a lesion in the duct is bleeding. The bleeding can be caused by an intraductal carcinoma (in-situ or invasive), a bleeding papilloma, or benign fibrocystic changes with an active intraductal component (eg, plasma cell mastitis, ductal ectasia, intraductal hyperplasia, or papillomatosis). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathologic (suspicious) nipple discharge'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Bloody or guaiac positive nipple discharge can also be seen in approximately 20 percent of women during pregnancy and lactation. The cause is usually hypervascularity of developing breast tissue, which is benign and requires no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. However, the evaluation of breast complaints in pregnancy and lactation can be complicated by the changing breast examination. Referral for surgical evaluation and biopsy is warranted for evaluation and management of bloody nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Guaiac positive discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple secretion that is not grossly bloody, but is guaiac positive, is usually caused by intraductal pathologies (eg, papilloma, papillomatosis, and hyperplasia) or plasma cell mastitis with duct ectasia, which is a chronic inflammatory condition, and occasionally breast carcinoma. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathologic (suspicious) nipple discharge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Staining of the bra without obvious nipple discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman may report finding a stain or spot of blood on her brassiere or underclothing [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/29\">",
"     29",
"    </a>",
"    ]. This merits careful examination of the skin around the nipple and nipple areolar complex. While skin changes such as dermatitis or eczema and associated excoriations can occur, it is important to rule out Paget disease with a skin biopsy if the lesions persist after conservative treatment. Paget disease is a breast cancer, characterized clinically by an eczematoid appearance with nipple crusting, scaling, or erosion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H12#H12\">",
"     \"Breast biopsy\", section on 'Skin punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the skin is intact and no discharge can be elicited and the rest of the physical examination and radiologic evaluation is negative, then short-term clinical follow-up is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast imaging and laboratory testing should be tailored to the patient's presentation. In general, after clinical evaluation and physical examination, all women presenting with pathologic nipple discharge should undergo a periareolar ultrasound. A mammogram should be performed for women &ge;30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Additional imaging modalities are discussed in detail below.",
"   </p>",
"   <p>",
"    Surgical evaluation is indicated if there is a breast mass, any imaging abnormality, positive guaiac test, or the discharge is spontaneous, uniductal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bloody. Surgical evaluation of pathologic nipple discharge is required for diagnosis and treatment even if imaging results are negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If physical examination is otherwise normal, imaging is negative, and the discharge is multiductal and guaiac negative, then the patient will need laboratory tests, medical evaluation, and galactorrhea workup. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A guide to management is provided by the algorithm shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef54471 \" href=\"UTD.htm?19/3/19518\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiductal discharge should be evaluated with a pregnancy test, prolactin levels, renal and thyroid function tests, and appropriate endocrinological follow-up if there are abnormal findings. These tests are not indicated for evaluation of uniductal discharge. Further endocrinological evaluation is also indicated if there are other systemic abnormalities, such as menstrual irregularity, infertility, headaches, visual disturbances, or symptoms of hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are helpful because they may reveal an underlying abnormality in the duct (or elsewhere in the breast) and help direct the surgical evaluation.",
"   </p>",
"   <p>",
"    Multiple imaging modalities for evaluation of the breast are available; we recommend mammography and ultrasound examination as a starting point. Although the sensitivity of mammography is low, it is the best modality for identifying suspicious lesions in the breast. Ultrasound is especially useful for identifying lesions within the ducts that can be subjected to core biopsy or localized for surgical biopsy. In addition, ductography is often used to delineate an intraductal filling defect which may be causing the nipple discharge.",
"   </p>",
"   <p>",
"    Cytology is rarely helpful and is not recommended. Other diagnostic testing, including breast magnetic resonance imaging, magnetic resonance ductography, ductal lavage, and ductoscopy can be helpful in selected women but are not always necessary for the work up of nipple discharge. Each of these diagnostic tools is discussed below.",
"   </p>",
"   <p>",
"    Imaging does not reliably identify all cancers or high risk lesions, such as papilloma or atypia. Surgical evaluation of pathologic nipple discharge is required for diagnosis and treatment even if imaging results are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Mammography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts recommend that a mammogram be performed in women with non-lactational spontaneous discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This is usually limited to women at least 30 years of age. Mammograms may fail to show cancers or high risk lesions if they are small, lack calcifications, or are entirely intraductal [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/32\">",
"     32",
"    </a>",
"    ]. If an abnormality is detected, core biopsy with clip placement should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H3#H3\">",
"     \"Breast biopsy\", section on 'Stereotactic biopsy'",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The sensitivity and specificity of mammography for detection of cancer or high-risk lesions such as papilloma or atypia ranges from 7 to 10 and 94 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/13,33\">",
"     13,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link\">",
"     \"Breast imaging: Mammography and ultrasonography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound provides a useful tool for the diagnosis of ductal disease as it is directed to the periareolar area and provides visualization of dilated ducts (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83705 \" href=\"UTD.htm?43/45/44756\">",
"     image 1",
"    </a>",
"    ), and any nodules inside them (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83702 \" href=\"UTD.htm?37/1/37909\">",
"     image 2",
"    </a>",
"    ). It allows visualization of ductal pathology as small as 0.5 mm in diameter and can be used for ultrasound guided percutaneous biopsy of lesions and ultrasound guided wire localization for surgery. If core biopsy is performed, a clip should be placed to allow subsequent localization if surgery is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H4#H4\">",
"     \"Breast biopsy\", section on 'Core needle biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 52 patients with suspected ductal disease, ultrasonography had a sensitivity of 97 percent and a specificity of 60 percent with a positive predictive value of 95 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H29#H29\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Role of ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Ductography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductography is a delicate, technically challenging study that requires installation of iodine containing contrast medium into the discharging duct [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/32,35,36\">",
"     32,35,36",
"    </a>",
"    ]. The intraductal lesion will appear as an intraductal filling defect, a complete ductal obstruction, or a wall irregularity. Ductography can only be performed if the nipple discharge is reproducible on physical examination and if the duct can be cannulated. In a series of 306 patients with suspicious nipple discharge and negative standard evaluation (breast exam, mammogram, and ultrasound), 163 underwent ductography. Successful cannulation was achieved in 88 percent. Ductography was associated with a sensitivity of 76 percent and specificity of 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/36\">",
"     36",
"    </a>",
"    ]. The positive predictive value of ductography in this series was 19 percent.",
"   </p>",
"   <p>",
"    The absence of a lesion on ductogram does not exclude a cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. However, if ductography is successful, it may help identify the location of the lesion, which can aid the surgeon in more precisely localizing the proper area at the time of surgery, thereby limiting the amount of tissue excised.",
"   </p>",
"   <p>",
"    Ductography should not be performed in patients with mastitis or a breast abscess as this could worsen the inflammation. Ductography can cause mastitis if too much contrast material is injected or if too much pressure is used during injection, resulting in perforation of the duct and extravasation of contrast material.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is a relatively sensitive imaging modality with low to moderate specificity. The role of MRI in the evaluation of nipple discharge is evolving [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/37\">",
"     37",
"    </a>",
"    ]. In 52 patients with suspicious nipple discharge who were studied with a breast MRI; the sensitivity and specificity for malignancy were 77 and 62 percent, respectively, with a median followup of 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/36\">",
"     36",
"    </a>",
"    ]. The positive predictive value of MRI in this series was 56 percent. The significant false positive rate and somewhat limited availability of MR-guided biopsy limits the utility of this modality. If MR is going to be used in this setting, it should be done in a facility that has MR biopsy capabilities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=see_link&amp;anchor=H633667#H633667\">",
"     \"MRI of the breast and emerging technologies\", section on 'Indications for breast MRI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     MR ductography",
"    </span>",
"    &nbsp;&mdash;&nbsp;MR ductography is a different technique than standard breast MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/38\">",
"     38",
"    </a>",
"    ]. It utilizes heavy T2 weighting, which accentuates the visibility of fluid containing structures. No directly instilled or intravenous contrast material is necessary. MR ductography provides a three dimensional image and can show the precise shape and location of the abnormal duct and lesion in the breast. However, this technique will not reveal ducts that are not dilated or those with low signal intensity on heavily T2-weighted images, due to hemorrhage or the presence of proteinaceous contents within the duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cytologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;No definite benefits have been identified for the routine use of cytology in the evaluation of nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/24\">",
"     24",
"    </a>",
"    ]. Systematic cytologic examination of all nipple discharge is not cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective study of 618 patients with nipple discharge over a 14 year period, the sensitivity and specificity of cytology were 17 and 66 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/15\">",
"     15",
"    </a>",
"    ]. In this series, only one malignant lesion was diagnosed with cytology alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Ductoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductoscopy can be employed as a minimally invasive method for evaluation and treatment of nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. It was first introduced in 1988 and the size and resolution of the scopes has improved significantly over time [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/42\">",
"     42",
"    </a>",
"    ]. As with ductography, ductoscopy requires a reproducible discharge and the ability to cannulate and dilate the discharging duct.",
"   </p>",
"   <p>",
"    Ductoscopy involves placing a small fiberoptic cannula in the discharging duct; the procedure can be done in the office or in the operating room. The newest scopes have an outer diameter of 0.9 mm with a 0.2 mm working channel attachment that can be used for insufflation and tissue sampling. Ductoscopic biopsy is also possible in some cases and obviates the need to excise the surgical duct.",
"   </p>",
"   <p>",
"    In a retrospective series of 114 women evaluated for nipple discharge or abnormal ductal lavage cytology, half were evaluated with ductoscopic guidance and half with surgery alone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/43\">",
"     43",
"    </a>",
"    ]. Ductoscopy was attempted in 68 breasts and was unsuccessful in 9 cases (13 percent). The overall yield of pathologic diagnoses did not differ significantly when comparing ductoscopy with conventional surgery (88 versus 81 percent with conventional surgery).",
"   </p>",
"   <p>",
"    Advocates of this procedure point out that ductoscopy allows for visualization of more peripheral lesions and may serve to decrease surgical duct excisions for benign entities [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/42\">",
"     42",
"    </a>",
"    ]. Further study and refinement of this technique is needed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Ductal lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ductal lavage is a means to increase the scant cellularity of specimens obtained by expression or aspiration of nipple discharge for cytology. The procedure involves cannulation of each fluid-yielding duct with a single lumen catheter; saline is instilled through the catheter and then removed. The effluent is immediately fixed and centrifuged to recover a cell pellet. The effectiveness of this technique has been questioned, because the cancer-filled duct may not always yield fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/40\">",
"     40",
"    </a>",
"    ]. Even if cells are obtained on lavage, this does not help localize the lesion. Furthermore, this is an extension of cytologic evaluation of the breast and suffers from the same limitations. In general, cytology of the discharge or of a ductal lavage specimen does not impact management. That is, a benign result is not a substitute for pathologic evaluation and a positive result does not provide a reliable diagnosis, especially in cases where atypia is reported. Additionally, the technique is time-intensive, expensive, and requires expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Skin punch biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women sometimes present with a complaint of nipple discharge but are found to have skin lesions on the nipple rather than true nipple discharge. These lesions can have the appearance of dermatitis or eczema with erythematous lesions that weep or bleed. These can be the first signs of Paget disease of the breast, an unusual breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although a short term course of treatment with steroid cream can be considered, if the lesions do not resolve within two weeks, or recur after treatment, such skin lesions should be subjected to a punch biopsy for definitive diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H12#H12\">",
"     \"Breast biopsy\", section on 'Skin punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Medical treatment for physiologic nipple discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is taking a medication that has been associated with galactorrhea (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , phenothiazines, selective serotonin reuptake inhibitors), and the breast evaluation is otherwise negative, the patient should be educated that this is a side effect of the medication. In some cases, continuing the medication is appropriate (as an example, antipsychotic drugs). If the symptom of ongoing nipple discharge is bothersome to the patient, the medication can be tapered or changed in consultation with the prescribing clinician. Treatment of hyperprolactinemia is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=see_link\">",
"     \"Treatment of hyperprolactinemia due to lactotroph adenoma and other causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Surgical treatment for pathologic nipple discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a full evaluation has ruled out malignancy, pathologic nipple discharge in nonlactating women should be managed by a terminal duct excision. If a core needle biopsy has demonstrated ductal carcinoma in situ or invasive breast cancer, appropriate cancer surgery should be planned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H7#H7\">",
"     \"Breast conserving therapy\", section on 'Patient selection for BCT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a core biopsy was not possible or non-diagnostic, a terminal duct excision is necessary to treat the nipple discharge and confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/46\">",
"     46",
"    </a>",
"    ]. A terminal duct excision is usually approached through a circumareolar incision and removes tissue at least 2 to 3 cm distal from the nipple. When a single duct can be implicated, the surgeon should direct the resection to the site of concern, attempting to preserve the non-affected duct such that lactation may still be possible.",
"   </p>",
"   <p>",
"    An intraductal papilloma can be resected over a lacrimal duct probe gently placed in the duct [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/47\">",
"     47",
"    </a>",
"    ]. Alternatively, a nipple flap duct resection can be performed. In this procedure, the areolar skin is dissected back with a gentle teasing dissection to the subareolar region where the abnormal duct can be identified as larger and darker than the other lactiferous ducts. The ductal abnormality can be confirmed by gentle occlusion of the duct with a hemostat, which will demonstrate that the nipple secretion no longer flows. The duct is then resected by ligation of its cutaneous end followed by dissection and excision of the length of duct that appears abnormal and its intraluminal lesion.",
"   </p>",
"   <p>",
"    Another approach is to perform preoperative ductography with instillation of a mixture of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    and radiopaque dye, which can provide a visual image of the course of the duct as well as aid in intraoperative identification of the targeted duct, which will be filled with blue dye. This can help limit the dissection to the area of the intraductal lesion and increase the likelihood of identifying a lesion at pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/23/3449/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central (total) terminal duct excision is occasionally used for intractable discharge from multiple ducts that is causing significant distress to the patient. A period of observation with no nipple stimulation is recommended prior to proceeding to surgical therapy. It is important to discuss with premenopausal women that this will preclude lactation in the future. Some women can still breast-feed after a localized excision of a single duct, however the scarring associated with healing can still make this difficult or impossible and women should be counseled as to this possibility. Terminal duct excision can also change the sensitivity of the nipple, including hyposensitivity and hypersensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=see_link\">",
"       \"Patient information: Common breast problems (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nipple discharge is categorized as normal (lactation), benign (physiologic), or pathologic based on the characteristics of presentation. Most nipple discharge is benign in origin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of nipple discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign physiologic unilateral or bilateral nipple discharge (galactorrhea) is characterized by multiductal discharge that tests negative for blood, regardless of color (eg, milky, brown, green, blue, gray, or clear). Galactorrhea is caused by hyperprolactinemia and may be secondary to medications, endocrine tumors (pituitary adenoma), endocrine abnormalities, or a variety of medical conditions. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Physiologic nipple discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pathologic discharge is characterized by spontaneous, persistent, unilateral discharge limited to one duct (uniductal). The discharge can be either serous (straw-colored or clear), sanguinous (bloody), or serosanguineous (blood-tinged). An intraductal papilloma is the cause of pathologic discharge in over half the cases, while underlying malignancy is the cause of nipple discharge in 5 to 10 percent of cases. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathologic (suspicious) nipple discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The workup of suspicious nipple discharge should include ultrasound and mammography. The role of imaging is to determine whether there are any underlying lesions that may account for the symptom of nipple discharge and to target the area for surgical localization. However, imaging studies do not reliably identify cancer or high-risk lesions in patients with nipple discharge. Other diagnostic testing, including ductography, breast magnetic resonance imaging, magnetic resonance ductography, and ductoscopy can be helpful in selected women but are not routinely necessary for the work-up of nipple discharge. Cytology and ductal lavage are rarely helpful. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical evaluation of pathologic nipple discharge with major duct excision is required for diagnosis and treatment even if the imaging results are negative. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Surgical treatment for pathologic nipple discharge'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/1\">",
"      Hussain AN, Policarpio C, Vincent MT. Evaluating nipple discharge. Obstet Gynecol Surv 2006; 61:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/2\">",
"      Isaacs JH. Other nipple discharge. Clin Obstet Gynecol 1994; 37:898.",
"     </a>",
"    </li>",
"    <li>",
"     Hughes, L, Mansel, R, Webster, D, Gravelle, I. Benign disorders and diseases of the breast. London, WB Saunders 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/4\">",
"      Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/5\">",
"      Murad TM, Contesso G, Mouriesse H. Nipple discharge from the breast. Ann Surg 1982; 195:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/6\">",
"      Jardines L. Management of nipple discharge. Am Surg 1996; 62:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/7\">",
"      King TA, Carter KM, Bolton JS, Fuhrman GM. A simple approach to nipple discharge. Am Surg 2000; 66:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/8\">",
"      Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 2002; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/9\">",
"      Buhimschi CS. Endocrinology of lactation. Obstet Gynecol Clin North Am 2004; 31:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/10\">",
"      Leung AK, Pacaud D. Diagnosis and management of galactorrhea. Am Fam Physician 2004; 70:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/11\">",
"      Morley JE, Dawson M, Hodgkinson H, Kalk WJ. Galactorrhea and hyperprolactinemia associated with chest wall injury. J Clin Endocrinol Metab 1977; 45:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/12\">",
"      Gioffr&egrave; Florio M, Manganaro T, Pollicino A, et al. Surgical approach to nipple discharge: a ten-year experience. J Surg Oncol 1999; 71:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/13\">",
"      Vargas HI, Vargas MP, Eldrageely K, et al. Outcomes of clinical and surgical assessment of women with pathological nipple discharge. Am Surg 2006; 72:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/14\">",
"      Nelson RS, Hoehn JL. Twenty-year outcome following central duct resection for bloody nipple discharge. Ann Surg 2006; 243:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/15\">",
"      Kooistra BW, Wauters C, van de Ven S, Strobbe L. The diagnostic value of nipple discharge cytology in 618 consecutive patients. Eur J Surg Oncol 2009; 35:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/16\">",
"      Woods ER, Helvie MA, Ikeda DM, et al. Solitary breast papilloma: comparison of mammographic, galactographic, and pathologic findings. AJR Am J Roentgenol 1992; 159:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/17\">",
"      Lewis JT, Hartmann LC, Vierkant RA, et al. An analysis of breast cancer risk in women with single, multiple, and atypical papilloma. Am J Surg Pathol 2006; 30:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/18\">",
"      Valdes EK, Feldman SM, Boolbol SK. Papillary lesions: a review of the literature. Ann Surg Oncol 2007; 14:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/19\">",
"      Mercado CL, Hamele-Bena D, Oken SM, et al. Papillary lesions of the breast at percutaneous core-needle biopsy. Radiology 2006; 238:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/20\">",
"      Sydnor MK, Wilson JD, Hijaz TA, et al. Underestimation of the presence of breast carcinoma in papillary lesions initially diagnosed at core-needle biopsy. Radiology 2007; 242:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/21\">",
"      Ciatto S, Andreoli C, Cirillo A, et al. The risk of breast cancer subsequent to histologic diagnosis of benign intraductal papilloma follow-up study of 339 cases. Tumori 1991; 77:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/22\">",
"      Seltzer MH, Perloff LJ, Kelley RI, Fitts WT Jr. The significance of age in patients with nipple discharge. Surg Gynecol Obstet 1970; 131:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/23\">",
"      Klimberg VS. Nipple discharge: more than pathologic. Ann Surg Oncol 2003; 10:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/24\">",
"      Simmons R, Adamovich T, Brennan M, et al. Nonsurgical evaluation of pathologic nipple discharge. Ann Surg Oncol 2003; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/25\">",
"      Chen L, Zhou WB, Zhao Y, et al. Bloody nipple discharge is a predictor of breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2012; 132:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/26\">",
"      KLINE TS, LASH SR. THE BLEEDING NIPPLE OF PREGNANCY AND POSTPARTUM PERIOD; A CYTOLOGIC AND HISTOLOGIC STUDY. Acta Cytol 1964; 8:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/27\">",
"      Lafreniere R. Bloody nipple discharge during pregnancy: a rationale for conservative treatment. J Surg Oncol 1990; 43:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/28\">",
"      Scott-Conner CE, Schorr SJ. The diagnosis and management of breast problems during pregnancy and lactation. Am J Surg 1995; 170:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/29\">",
"      Maier WP, Rosemond GP, Harasym EL Jr, et al. Paget's disease in the female breast. Surg Gynecol Obstet 1969; 128:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/30\">",
"      Gray RJ, Pockaj BA, Karstaedt PJ. Navigating murky waters: a modern treatment algorithm for nipple discharge. Am J Surg 2007; 194:850.",
"     </a>",
"    </li>",
"    <li>",
"     CRICO/RMF Breast care management algorithm 2009 in preparation. www.rmf.harvard.edu/bca (2004 version) (Accessed on March 1, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/32\">",
"      Sickles EA. Galactography and other imaging investigations of nipple discharge. Lancet 2000; 356:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/33\">",
"      Adepoju LJ, Chun J, El-Tamer M, et al. The value of clinical characteristics and breast-imaging studies in predicting a histopathologic diagnosis of cancer or high-risk lesion in patients with spontaneous nipple discharge. Am J Surg 2005; 190:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/34\">",
"      Ballesio L, Maggi C, Savelli S, et al. Adjunctive diagnostic value of ultrasonography evaluation in patients with suspected ductal breast disease. Radiol Med 2007; 112:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/35\">",
"      Cardenosa G, Doudna C, Eklund GW. Ductography of the breast: technique and findings. AJR Am J Roentgenol 1994; 162:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/36\">",
"      Morrogh M, Morris EA, Liberman L, et al. The predictive value of ductography and magnetic resonance imaging in the management of nipple discharge. Ann Surg Oncol 2007; 14:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/37\">",
"      Orel SG, Dougherty CS, Reynolds C, et al. MR imaging in patients with nipple discharge: initial experience. Radiology 2000; 216:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/38\">",
"      Hirose M, Nobusawa H, Gokan T. MR ductography: comparison with conventional ductography as a diagnostic method in patients with nipple discharge. Radiographics 2007; 27 Suppl 1:S183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/39\">",
"      Ciatto S, Bravetti P, Cariaggi P. Significance of nipple discharge clinical patterns in the selection of cases for cytologic examination. Acta Cytol 1986; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     Morrow, M, Jordan, VC. Role of breast epithelial sampling techniques. In: Managing Breast Cancer Risk, Decker, BC (Ed), London 2003. p.138.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/41\">",
"      Escobar PF, Crowe JP, Matsunaga T, Mokbel K. The clinical applications of mammary ductoscopy. Am J Surg 2006; 191:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/42\">",
"      Kapenhas-Valdes E, Feldman SM, Cohen JM, Boolbol SK. Mammary ductoscopy for evaluation of nipple discharge. Ann Surg Oncol 2008; 15:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/43\">",
"      Moncrief RM, Nayar R, Diaz LK, et al. A comparison of ductoscopy-guided and conventional surgical excision in women with spontaneous nipple discharge. Ann Surg 2005; 241:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/44\">",
"      Uchida K, Fukushima H, Toriumi Y, et al. Mammary ductoscopy: current issues and perspectives. Breast Cancer 2009; 16:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/45\">",
"      Khan SA, Wolfman JA, Segal L, et al. Ductal lavage findings in women with mammographic microcalcifications undergoing biopsy. Ann Surg Oncol 2005; 12:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/46\">",
"      Alcock C, Layer GT. Predicting occult malignancy in nipple discharge. ANZ J Surg 2010; 80:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/47\">",
"      Dennis MA, Parker S, Kaske TI, et al. Incidental treatment of nipple discharge caused by benign intraductal papilloma through diagnostic Mammotome biopsy. AJR Am J Roentgenol 2000; 174:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/23/3449/abstract/48\">",
"      Cabioglu N, Hunt KK, Singletary SE, et al. Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg 2003; 196:354.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 802 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3449=[""].join("\n");
var outline_f3_23_3449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF NIPPLE DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physiologic nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Medication related causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neurogenic stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathologic (suspicious) nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bilateral discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Unilateral discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Straw-colored or clear transparent discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Grossly bloody discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Guaiac positive discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Staining of the bra without obvious nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Mammography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Ductography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - MR ductography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cytologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Ductoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Ductal lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Skin punch biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Medical treatment for physiologic nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Surgical treatment for pathologic nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/802\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/802|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/3/19518\" title=\"algorithm 1\">",
"      Nipple discharge algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/802|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/45/44756\" title=\"diagnostic image 1\">",
"      Retroareolar dilated ducts - ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/1/37909\" title=\"diagnostic image 2\">",
"      Breast intraductal papilloma ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/802|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2988\" title=\"table 1\">",
"      Drugs cause hyperprolactinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22489?source=related_link\">",
"      Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/857?source=related_link\">",
"      Erythematous disorders of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/56/6018?source=related_link\">",
"      Patient information: Common breast problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6519?source=related_link\">",
"      Physiology of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31561?source=related_link\">",
"      Treatment of hyperprolactinemia due to lactotroph adenoma and other causes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_23_3450="ECG Mobitz type I AV block";
var content_f3_23_3450=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73051%7ECARD%2F62040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73051%7ECARD%2F62040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing Mobitz type I (Wenckebach) Atrioventricular (AV) block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 151px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single lead electrocardiogram (ECG) showing Mobitz type I (Wenckebach) second degree AV block with 5:4 conduction. The characteristics of this arrhythmia include: a progressively increasing PR interval until a P wave is not conducted (arrow); a progressive decrease in the increment in the PR interval; a progressive decrease in the RR interval; and the RR interval that includes the dropped beat (0.96 sec) is less than twice the RR interval between conducted beats (0.53 to 0.57 sec).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing concurrent Mobitz type I (Wenckebach) atrioventricular (AV) block and inferior myocardial infarction (MI)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 87px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This rhythm strip shows a Mobitz type I (Wenckebach) atrioventricular block with 4:3 and 3:2 conduction and progressive prolongation of the PR intervals of conducted beats. The marked ST segment elevation suggests acute inferior wall ischemia or infarction that may be responsible for the arrhythmia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3450=[""].join("\n");
var outline_f3_23_3450=null;
var title_f3_23_3451="ECG exercise and ST depression";
var content_f3_23_3451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relationship in exercise ECG testing between sensitivity, specificity, and the amount of ST segment depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Amount of ST depression",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specificity, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5 mm",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.0 mm",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.0 mm",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        98",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3451=[""].join("\n");
var outline_f3_23_3451=null;
var title_f3_23_3452="SSRI dosing adolescents";
var content_f3_23_3452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of selective serotonin reuptake inhibitors (SSRIs) for adolescent depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Starting dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average effective dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maximum dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoxetine* (Prozac)",
"       </td>",
"       <td>",
"        10 mg every morning&bull;",
"       </td>",
"       <td>",
"        20 mg every morning",
"       </td>",
"       <td>",
"        60 mg every morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citalopram (Celexa)",
"       </td>",
"       <td>",
"        10 mg every morning&bull;",
"       </td>",
"       <td>",
"        20 mg every morning",
"       </td>",
"       <td>",
"        40 mg every morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluvoxamine (Luvox)",
"       </td>",
"       <td>",
"        50 mg every morning&bull;",
"       </td>",
"       <td>",
"        100 - 150 mg each day",
"       </td>",
"       <td>",
"        100 mg twice per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxetine (Paxil)",
"       </td>",
"       <td>",
"        10 mg every morning&bull;",
"       </td>",
"       <td>",
"        20 mg every morning",
"       </td>",
"       <td>",
"        60 mg every morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline (Zoloft)",
"       </td>",
"       <td>",
"        25 mg every morning&bull;",
"       </td>",
"       <td>",
"        50 to 100 mg every morning",
"       </td>",
"       <td>",
"        150 mg every morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escitalopram (Lexapro)",
"       </td>",
"       <td>",
"        5 mg every morning",
"       </td>",
"       <td>",
"        10 mg every morning",
"       </td>",
"       <td>",
"        20 mg every morning",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Fluoxetine is considered the first-line agent and is the only one of these drugs that is approved by the US Food and Drug Administration for the treatment of depression in children and adolescents.",
"     <br>",
"      &bull; If medication causes continued sedation, it is appropriate to switch dose to evening instead of morning.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hagman, J Adolescent Health Update 2001; 13(3):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3452=[""].join("\n");
var outline_f3_23_3452=null;
var title_f3_23_3453="Major congenital malformations";
var content_f3_23_3453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major congenital malformations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Head and craniofacial structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Skull",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anencephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Encephalocele (occipital, frontal)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Holoprosencephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hydrocephaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Eyes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microphthalmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anophthalmia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colobomas (iris, retina)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Ears",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe microtia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mouth and throat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cleft lip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cleft palate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe micrognathia (Robin sequence)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Macro or microglossia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic hygroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pectus excavatum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent or hypoplastic clavicles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningomyelocele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spina bifida",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Omphalocele",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrochisis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ambiguous genitalia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extremities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Arms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent or limb deficiencies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Hands and feet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Polydactyly, complete syndactyly, polysyndactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absent digits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ectrodactyly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular and great vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tetralogy of Fallot",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Truncus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoplastic left heart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular or atrial septal defect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transposition of the great vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interrupted aortic arch type B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total anomaly of pulmonary venous return",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoplasia or coarctation of the aorta",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3453=[""].join("\n");
var outline_f3_23_3453=null;
var title_f3_23_3454="IV rx IVC-related infxs";
var content_f3_23_3454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous antimicrobial treatment of intravenous catheter-related bloodstream infection according to the specific pathogen isolated",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Pathogen",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preferred antimicrobial agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Alternative antimicrobial agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Gram-positive cocci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       <em>",
"        Staphylococcus aureus",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Methicillin susceptible",
"      </td>",
"      <td>",
"       Nafcillin or oxacillin*",
"      </td>",
"      <td>",
"       Cefazolin or vancomycin",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Methicillin resistant",
"      </td>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       Daptomycin&Delta; or linezolid",
"      </td>",
"      <td>",
"       Strains of",
"       <em>",
"        S. aureus",
"       </em>",
"       with reduced susceptibility or resistance to vancomycin have been reported; strains resistant to linezolid and strains resistant to daptomycin have been reported",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       Coagulase-negative staphylococci",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Methicillin susceptible",
"      </td>",
"      <td>",
"       Nafcillin or oxacillin",
"      </td>",
"      <td>",
"       First-generation cephalosporin or vancomycin",
"      </td>",
"      <td>",
"       Vancomycin has dosing advantages over nafcillin and oxacillin, but the latter are preferred because of concerns about increasing vancomycin resistance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Methicillin resistant",
"      </td>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       Daptomycin, linezolid, or quinupristin/dalfopristin&Delta;",
"      </td>",
"      <td>",
"       Strains resistant to linezolid have been reported",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       <em>",
"        Enterococcus faecalis/Enterococcus faecium",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ampicillin susceptible",
"      </td>",
"      <td>",
"       Ampicillin (or penicillin) &plusmn; gentamicin",
"      </td>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       Vancomycin may have dosing advantages over ampicillin, but there are concerns about Vm resistance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ampicillin resistant, Vancomycin susceptible",
"      </td>",
"      <td>",
"       Vancomycin &plusmn; gentamicin",
"      </td>",
"      <td>",
"       Linezolid or daptomycin&Delta;",
"      </td>",
"      <td>",
"       Quinupristin/dalfopristin is not effective against",
"       <em>",
"        E. faecalis",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Ampicillin resistant, Vancomycin resistant",
"      </td>",
"      <td>",
"       Linezolid or daptomycin&Delta;",
"      </td>",
"      <td>",
"       Quinupristin/dalfopristin&Delta;",
"      </td>",
"      <td>",
"       Susceptibility of Vancomycin-resistant enterococci isolates varies; quinupristin/dalfopristin is not effective against",
"       <em>",
"        E. faecalis",
"       </em>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Gram-negative bacilli&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"4\">",
"       <em>",
"        Escherichia coli",
"       </em>",
"       and",
"       <em>",
"        Klebsiella",
"       </em>",
"       species",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       ESBL negative",
"      </td>",
"      <td>",
"       Third-generation cephalosporin (eg ceftriaxone)",
"      </td>",
"      <td>",
"       Ciprofloxacin or aztreonam",
"      </td>",
"      <td>",
"       Susceptibility of strains varies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       ESBL positive",
"      </td>",
"      <td>",
"       Carbapenem (eg ertapenem, imipenem, meropenem or doripenem)",
"      </td>",
"      <td>",
"       Ciprofloxacin or aztreonam",
"      </td>",
"      <td>",
"       Susceptibility of strains varies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Enterobacter species",
"       </em>",
"       and",
"       <em>",
"        Serratia marcescens",
"       </em>",
"      </td>",
"      <td>",
"       Carbapenem (eg ertapenem, imipenem or meropenem)",
"      </td>",
"      <td>",
"       Cefepime or ciprofloxacin",
"      </td>",
"      <td>",
"       Susceptibility of strains varies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Acinetobacter",
"       </em>",
"       species",
"      </td>",
"      <td>",
"       Ampicillin/sulbactam or carbapenem (eg imipenem or meropenem)",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       Susceptibility of strains varies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Stenotrophomonas maltophilia",
"       </em>",
"      </td>",
"      <td>",
"       TMP-SMZ",
"      </td>",
"      <td>",
"       Ticarcillin-clavulanate",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Pseudomonas aeruginosa",
"       </em>",
"      </td>",
"      <td>",
"       Fourth-generation cephalosporin (cefepime) or carbapenem (imipenem or meropenem) or piperacillin-tazobactam, with or without aminoglycoside (tobramycin)",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       Susceptibility of strains varies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Burkholderia cepacia",
"       </em>",
"      </td>",
"      <td>",
"       TMP-SMZ or carbapenem (imipenem or meropenem)",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       Other species, such as",
"       <em>",
"        B. acidovorans",
"       </em>",
"       and",
"       <em>",
"        B. pickieii",
"       </em>",
"       , may be susceptible to same antimicrobial agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Uncommon pathogens",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Corynebacterium jeikeium",
"       </em>",
"       (group JK)",
"      </td>",
"      <td>",
"       Vancomycin",
"      </td>",
"      <td>",
"       Linezolid (based on in vitro activity)",
"      </td>",
"      <td>",
"       Check susceptibilities for other corynebacteria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Chryseobacterium (Flavobacterium)",
"       </em>",
"       species",
"      </td>",
"      <td>",
"       Levofloxacin",
"      </td>",
"      <td>",
"       TMP-SMZ or imipenem or meropenem",
"      </td>",
"      <td>",
"       Based on in vitro activity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Ochrobacterium anthropi",
"       </em>",
"      </td>",
"      <td>",
"       TMP-SMZ or ciprofloxacin",
"      </td>",
"      <td>",
"       Imipenem, meropenem, ertapenem or doripenem plus aminoglycoside",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <em>",
"        Malassezia furfur",
"       </em>",
"      </td>",
"      <td>",
"       Amphotericin B",
"      </td>",
"      <td>",
"       Voriconazole",
"      </td>",
"      <td>",
"       Intravenous lipids should be discontinued; some experts recommend removal of catheter",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    See",
"    <em>",
"     S. aureus",
"    </em>",
"    section of the text regarding important antibiotic management issues concerning linezolid.",
"    <br>",
"     TMP-SMX: Trimethoprim-sulfamethoxazole",
"     <br>",
"      ESBL: Extended spectrum beta lactamase",
"      <div class=\"footnotes\">",
"       * Penicillin, if the strain is susceptible.",
"       <br>",
"        &bull; Pending susceptibility results for the isolate.",
"        <br>",
"         &Delta; Pediatric experience with daptomycin and quinupristin/dalfopristin is limited",
"        </br>",
"       </br>",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3454=[""].join("\n");
var outline_f3_23_3454=null;
var title_f3_23_3455="Course of chronic HBV";
var content_f3_23_3455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Course of chronic HBV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 340px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The course of chronic HBV infection is considered to consist of&nbsp;four phases: immune tolerance, immune clearance (HBeAg-positive chronic hepatitis), inactive carrier, and reactivation (HBeAg-negative chronic hepatitis), although not all patients go through every phase. HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; HBV, hepatitis B virus; ALT, alanine aminotransferase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43:S173. Copyright &copy; 2006 John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_23_3455=[""].join("\n");
var outline_f3_23_3455=null;
